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1 Introduction 
 
Despite increasing effort in finding efficient treatments for osteoarthritis (OA), which is a 
major cause of morbidity and loss of joint function in the elderly population, many patients 
with OA still suffer from pain symptoms and disability.[1] Up to now, no medical therapy has 
been shown to clearly halt or reverse OA progression, the related extracellular matrix (ECM) 
degradation, and the joint cavity inflammation followed by it. Hyaluronic acid (HA) is a main 
component of articular cartilage that endows synovial fluid (SF) with its viscoelastic 
properties and thereby provides lubrication for the articular surfaces.[2] As OA progresses, 
inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukins are 
released, which lead to ECM degradation[3] and reduction of specific cartilage matrix proteins 
such as collagen type II and aggrecan. At the same time, natural HA concentration decreases, 
which deteriorates the mechanical/viscoelastic properties of the SF.[4] Intra-articular HA 
administration, the standard treatment of OA, aims to restore these properties,[5] although HA 
is prone to enzymatic digestion and there is controversy over its underlying attributes. Slowly 
degradable injectable hydrogels with tunable mechanical and anti-inflammatory properties 
may pose a promising approach. Dendritic polyglycerol sulfate (dPGS), which has shown to 
prevent inflammatory responses,[6] is used in this work to form a hydrogel through 
crosslinkage of dPGS-N3 with polyethylene glycol-dicyclooctyne (PEG-DIC) in a 
cytocompatible reaction. The viscoelastic properties of the obtained gels can be effectively 
tuned by varying the molar ratio of the building blocks.[7] Since preserving and restoring the 
smooth articular surface is a primary goal of OA therapy, the tunable mechanical potential of 
dPGS-based hydrogel combined with its anti-inflammatory properties could be used to 
influence the OA alterations in a therapeutic sense. Therefore, the main topic of this study 
was to determine a suitable concentration for intra-articular injections of dPGS hydrogel that 
mimics HA in terms of its viscoelastic/mechanical properties, characterize the biological 
influence of the dPGS-based hydrogel on normal and OA-like tissue-engineered cartilage, and 
compare it with clinically used HA. 
1.1 Synovial joint 
 
Joints can be classified functionally or structurally, based on how much movement they allow 
and what kind of tissue structure is present in the joint, respectively. Structurally categorized, 
synovial joints are the most common type in the body, linking the musculoskeletal system and 
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facilitating its movement.[8] The synovial joint consists of SF within a cavity surrounded by 
articular cartilage and synovial membrane (Figure 1).  
1.1.1 Synovial membrane 
Synovial membrane also called synovium is a vascularized, thin layer of connective tissue 
consisting of macrophage-like (type A) and fibroblast-like (type B) cells embedded in an 
ECM composed mainly of HA, collagen, and proteoglycans.[9] The fibroblast-like cells 
provide the ECM that supports the structure of the synovium and are responsible for 
producing the viscous SF that lubricates the joint during movement and nourishes avascular 
cartilage.[10] The tissue-specific function of macrophages is presumed to be included in joint 
homeostasis.[11] Joint injury and disease affecting the blood-joint barrier may impair the 
process of SF formation, resulting in pathologic SF.[9] Furthermore, in pathological situations, 
activated synovial cells are known to amplify the release of enzymes and factors that 
contribute to the destruction of the cartilage matrix.[12] 
1.1.2 Synovial fluid 
A key structural characteristic for a synovial joint is the presence of a joint cavity that is not 
seen at fibrous or cartilaginous joints. This space is filled with SF (synovia = “a thick fluid”), 
a protein-rich fluid (a blood plasma dialysate), containing lubricant molecules, mainly 
hyaluronic acid (HA) and proteoglycan 4 (PRG4, also known as lubricin and superficial zone 
protein).[13] 
SF is secreted into the joint cavity by fibroblast-like cells of the synovial membrane,[9] 
and provides lubrication to reduce friction between the articular cartilage surfaces at bone 
ends.[14] Furthermore, it facilitates the transport of nutrients and waste products including 
proteins and metabolites between the vascularized synovial membrane and the avascular 
cartilage.[9]  
1.1.3 Articular cartilage 
The glassy, highly specialized connective tissue at the end of the bones in synovial joints is 
termed articular cartilage.[15] Articular cartilage is avascular, aneural, and alymphatic with a 
low cell density, which contributes to limited intrinsic repair capacity.[16] Therefore, even 
minor injuries may lead to progressive damage and joint degeneration that result in significant 
pain and disability.[16-17] 
2
Structure and composition 
Due to changes in structure and composition of articular cartilage, it has been divided into 
four distinct zones; (I) the superficial zone, (II) the transitional or middle zone, (III) the deep 
or radial zone, and (IV) the zone of calcified cartilage. These layers consist of water (up to 
80% of wet weight in the surface zone and 65% within the deep zone), collagen (10-15% of 
wet weight,) and non-collagen proteins (5-10% of wet weight). The synthesis, maintenance, 
and degradation of these proteins are managed by chondrocytes, the only cell type in cartilage 
(5% of tissue volume).[18] There are five collagen types present in the articular cartilage; 
collagen II, VI, IX, X, and XI with type II being the most abundant one that makes up 95% of 
the solid composition of the mature human articular cartilage.[19] The most abundant non-
collagenous components in mammalian cartilage are proteoglycans (PGs). The basic PG unit 
consists of a core protein with one or more covalently attached glycosaminoglycan (GAG) 
chains including chondroitin sulfate, keratin sulfate, and HA.[20] The most abundant PG in 
mature articular cartilage is aggrecan (Figure 1).[21]  
Figure 1. Schematic representation of the synovial joint and native articular cartilage. In articular cartilage, cells 
in the tangential zone are aligned parallel to the articular surface, cells in the middle zone are spherical and 
randomly distributed, while cells in the deep zone are aligned perpendicular to the tidemark and calcified zone 
and integrate with the subchondral bone. The matrix consists of a network of type II collagen fibers, which is 
reinforced by crosslinks formed between chains of hyaluronic acid, proteoglycans, and other non-collagenous 
proteins. Adapted from reference [21].  
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Function 
The dynamic functioning of synovial joint is facilitated by the presence of articular cartilage 
and is related to its mechanical and biomechanical properties. Type II collagen, the main 
structural protein of articular cartilage, arranges a meshwork that is sustained by non-
collagenous proteins (such as cartilage oligomeric matrix protein) and other collagen types. 
This network endows cartilage with tensile strength and provides a low-friction bearing 
surface that prevents bone-to-bone contact.[21-22] Water, absorbed by aggrecan and other 
embedded proteoglycans within this matrix, provides compressive resistance and permits a 
degree of shock absorbance during vigorous activities. Cartilage architecture and biochemical 
composition are arranged by chondrocytes.[21] In undamaged conditions, chondrocytes are in a 
quiescent state holding a fine balance between synthetic and catabolic activities.[23] However, 
degenerative joint diseases, traumatic cartilage injuries, and aging result in loss of 
homeostatic conditions and up-regulation of catabolic pathways.[23-24] 
1.2 Osteoarthritis 
 
OA is the most common degenerative joint disease worldwide, which affects about 40 million 
people in Europe.[25] Although OA can affect every synovial joint, it is more frequent in the 
knee, hip, spine, and hand. It is characterized by pain, transient morning stiffness (reduced 
mobility), and crepitus on joint motion (a cracking sound or sensation produced in the joint). 
OA can be classified as primary (idiopathic) and secondary. Primary OA does not have any 
identifiable cause, such as an injury and results from a combination of risk factors with 
increasing age and obesity being the most prominent. Secondary OA is based on the 
attribution to recognized causative factors such as trauma and surgery on the joint 
structure.[26] It is known that prior to the age of 40, the incidence is lower and mostly 
secondary OA occurs, commonly due to trauma. The prevalence increases between 40 and 60 
years of age, and afterward a linear increase in the prevalence in later ages is observed. It is 
estimated that 9.6% of men and 18% of women of 60 or older probably have symptomatic 
OA.[27] 
 Understanding the pathophysiology of OA is still evolving, from being considered as 
cartilage-limited to a multifactorial disorder that disturbs the whole joint, including alteration 
in the articular cartilage, subchondral bone, ligaments, capsule and synovial membrane, 
ultimately leading to joint failure.[28] Cartilage degradation in OA can become stimulated as 
the result of a complex interplay of genetic, environmental, metabolic, and biochemical 
factors. However, the exact underlying mechanism is still unclear. Dysfunctional 
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chondrocytes and cartilage damage play a key role in the development of synovial 
inflammation.[29] Proteinases released by chondrocytes lead to the formation of pro-
inflammatory cartilage debris. These pieces of debris interact with other receptors on 
chondrocytes such as integrins and toll-like receptors and thereby enhance the expression of 
inflammatory and catabolic products. As they are in the synovial fluid, they act on the 
synovium to induce inflammation that in turn generates additional catabolic products. These 
products feedback on chondrocytes to further deregulate their function.[30] 
 There are several main factors that drive OA progression including pro-inflammatory 
cytokines (IL-1β, TNF-α),[31] chemokines,[32] ECM degrading enzymes, such as matrix 
metalloproteinases (MMPs), which degrade collagen, and aggrecanases (a disintegrin and 
MMP with thrombospondin motifs (ADAMTS)). These enzymes are downstream key players 
in the inflammatory signaling cascade.[33] Thus, the synovial cells, as well as the chondrocytes 
themselves, are potential sources of cytokines that could induce chondrocytes to synthesize 
and secrete cartilage-degrading proteases and other OA mediators.[31] The biochemical 
changes together with biomechanical alterations disturb cartilage homeostasis and contribute 
to OA pathogenesis. 
 Another hallmark of degenerated cartilage is the phenotypic shift of chondrocytes 
toward hypertrophy. In addition, osseous outgrowths (osteophytes) often formed at the joint 
margins,[34] subchondral bone sclerosis,[35] meniscal tear and extrusion,[36] and synovial 
membrane inflammation (synovitis) may also happen due to the mechanical changes during 
OA (Figure 2).[37] Finally, all these implications lead to pain and loss of joint function. 
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Figure 2. OA cartilage. (a) The changes of articular structure during  
OA pathogenesis. (b) Cellular responses in OA-cartilage.[38] 
1.2.1 Main factors and players 
 
The risk factors for OA can be divided into those that act at the level of personal awareness 
and those that change the biomechanical stability of the joint. Person-level risk factors include 
aging, female sex, genetic factors, joint biomechanics, and obesity. The main joint-level risk 
factors are joint injury, repetitive joint use through leisure or occupation, and joint 
malalignment.[30] The Osteoarthritis Research Society International (OARSI), which is the 
premier organization in this field, has summarized three prevailing risk factors for OA in its 
2017's summit.[39] These include joint injury and altered biomechanics, aging, and systemic 
metabolic derangement (Figure 3). In this section, several important factors and their 
association to the compromised OA situation are introduced. 
 An important link between primary causes of OA is interleukin 6 (IL-6). Inhibition of 
IL-6 receptor with a monoclonal antibody, which is likely mediated by attenuated signal 
transducer and activator of transcription 3 (STAT3) signaling,[40] reduce cartilage lesions and 
synovitis.[41] IL-6 also increases the production of MMPs (-1, -3, -13) and aggrecanases 
(ADAMTS-4 and -5) in chondrocytes.[40] IL-6 can induce and reciprocally be induced by 
basic calcium phosphate (BCP), which is found in the SF of almost 50% of OA patients. 
Induction of IL-6 by BCP seems to form a positive feedback loop leading to cartilage 
damage, but the exact mechanism of how BCP crystals activate the chondrocytes remains 
unclear.[42] 
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 Recently, some studies suggested a role for mitochondrial dysfunction in OA 
pathogenesis.[43] Kim et al. uncovered a regulatory network between mitochondria, 
lysosomes, and peroxisomes and found that this interconnectedness is potentially mediated by 
fission protein 1 (Fis1), which is reduced in human OA chondrocytes.[44] 
 It is still a matter of debate whether metabolic derangement is a primary cause of OA. 
Animal models showed that diet-induced obesity or hypercholesterolemia can lead to OA-like 
changes.[45] Binding oxidized low-density lipoprotein (oxLDL) to the lectin-like oxidized-
LDL receptor 1 (LOX-1) during inflammation and oxidative stress increases the production of 
reactive oxygen species in articular chondrocytes. Loss of LOX-1 is protective against OA-
related damage.[46] 
 Sirtuins (SIRTs) are deacetylases that play important roles in DNA repair. SIRT1 
promotes chondrocyte survival and its loss corresponds to the disease stage.[47] SiRNA-
mediated knockdown or pharmacologic inhibition of SIRT1 leads to lower levels of 
transcripts for the clock gene Bmal-1, which controls cartilage homeostasis.  This correlates 
with increased cartilage damage.[48] 
 Rela/p65 is a key player in NF-kB signaling, which maintains chondrocyte homeostasis, 
with important roles in regulating the expression of SOX9[49] and ADAMTS5.[50] Deletion of 
Rela results in acceleration of OA-related joint damage, which mostly is mediated by 
increased chondrocyte apoptosis.[51] 
 Macrophages play an important role in the homeostasis of the healthy joint and mediate 
the pro-inflammatory and catabolic effects of alarmins (danger signals) by influencing factors 
such as TNF-α and IL-1β.[52] The superficial zone (SZ) cells that express PRG4/lubricin may 
also be significant in tissue homeostasis and repair by migrating to the site of injury.[53]  
 Fibulins are known to have functions in maintenance of basement membrane 
organization and elastic fiber formation. With age, fibulin 3 expression is decreased, which is 
associated with lower expression of PRG4. Fibulin 3 may be a trigger for lubricin 
maintenance and therefore important for maintaining progenitor cells in the SZ but can be lost 
with injury or aging.  
 Aging also leads to accumulation of senescent cells (SnCs) in the SZ. SnCs have a 
senescence-associated secretory phenotype (SASP), which includes the production of IL-6.[54] 
 As OA develops, cartilage fibrillates and releases ECM fragments/debris into the joint. 
Crystals that can be part of this debris induce and maintain an inflammatory cycle.[55] 
Interrupting these cycles by lubricants/viscosupplements may contribute to avoid OA 
progression. 
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Figure 3. Schematic summary of significantly associated primary causes (risk factors) for OA. Primary causes 
include injury and altered biomechanics, ageing, and systemic metabolic derangement (e.g., 
hypercholesterolemia). Green indicators represent a positive effect (protective against OA). Red indicators 
represent a negative effect (promoting OA). Arrows indicate a positive relationship (stimulatory effect), whereas 
blunt-ended arrows indicate an inhibitory effect. Based on reported evidence from the 2016-2017 literature.[39] 
 
1.2.2 Conventional treatments  
 
There is no cure for OA available up to now and the desired therapeutic goal is to fight 
against clinical symptoms and, if possible, to inhibit the progression. Different interventions 
are available for OA management, including non-pharmacological (lifestyle changes), 
pharmacological and surgical methods. Patients who cannot gain sufficient pain relief and do 
not retrieve joint function by non-operative methods should be considered for the ultimate OA 
treatment: the prosthetic replacement of the affected joint. The first line of treatment 
considered by American College of Rheumatology (ACR), European League Against 
Rheumatism (EULAR) and OARSI guidelines[56] are currently the non-pharmacological 
therapies. The most widely proposed in this category are listed in Table 1. 
 
Table 1. Most widely proposed non-pharmacological therapies for osteoarthritis. 
Non-pharmacological therapies  
Aerobics Weight reduction Thermal modalities 
Walking aids  Muscle strengthening Acupuncture  




Referral to a physical 
therapist 
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 Non-pharmacological therapies are not sufficient to achieve sustained pain relief and 
restoration of the joint function in many OA patients, which led to development of various 
pharmacological treatments including both the fast and slow-acting drug families (Table 2).  
  
Table 2. Most widely proposed pharmacological therapies for osteoarthritis. 
Fast-acting drugs Slow-acting drugs 
Acetaminophen (paracetamol)  Glucosamine 
Non-steroidal anti-inflammatory drugs (NSAIDs) Chondroitin sulfate 
Cyclooxygenase-2 (Cox-2) inhibitors S-adenosylmethionine 
Glucocorticoids  Avocado/soybean unsaponifiables 
Opioids Hyaluronic acid 
 
 The fast-acting drug family is mainly used for pain relief and to alleviate inflammation. 
The first stage of treatment consists of analgesics such as acetaminophen, however, it can 
trigger adverse hepatic events in patients with hepatic insufficiency[22]. Non-steroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase inhibitors (also called coxibs) are typical 
anti-inflammatory compounds that are used as analgesic treatments.[57] However, NSAID are 
associated with gastrointestinal (nausea, vomiting, and constipation), renal and cardiovascular 
toxicity.[58] Intra-articular administration of glucocorticoids can rapidly eliminate joint 
effusion after inflammation, but is associated with a high risk of infection[59] and exhibits 
adverse metabolic events. Opioids are only used if other drugs do not provide sufficient pain 
relief and for patients with intolerance to other pharmacological treatments. However, they 
show a wide range of adverse events such as gastrointestinal dysfunction, alteration in the 
cognitive function, dependence, and respiratory depression.[58] In addition, there is the group 
of slow-acting drugs in osteoarthritis (SADOA) with long lasting effects, such as pain 
prevention as well as attenuation of cartilage destruction (e.g., HA, glucosamine, chondroitin 
sulfate).[29] The effects of SADOA are not yet clear but are known to have several anti-
inflammatory properties that block the pain receptors and may have influence on the 
viscoelastic properties of the cartilaginous tissue. The use of viscosupplementation is growing 
worldwide due to the positive effects on pain relief, lubrication, and joint functional 
amelioration.[59]  
1.2.3 Viscosupplementation with hyaluronic acid  
 
HA is a major component of the SF, which acts as a shock absorber to protect the cartilage 
against mechanical injuries. It endows SF with its viscoelastic properties and thereby provides 
lubrication for the articulating surfaces.[2] HA is an anionic, nonsulfated glycosaminoglycan, 
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composed of repeating D-glucuronic acid and N-acetyl-D-glucosamine.[60] It can bind to large 
amounts of water and it is found in human synovial fluid in a macropolymeric form with an 
average molecular weight of 3–4 million Dalton.[61] As OA progresses, natural HA 
concentration decreases into the lower ranges of HA molecular weight, leading to a 
deterioration of the mechanical/viscoelastic properties of the SF.[4] Viscosupplementation 
with HA, the standard treatment for OA, aims to restore these properties.[5] The pain relief 
may be due to the improvement of viscoelastic or mechanical properties of SF, i.e., 
lubrication, resistance to shear, and cushioning for the joint. Others propose biological 
mechanisms of action beside shock absorption and joint lubrication, including, anti-
inflammatory effects, chondroprotection, proteoglycan synthesis, and cartilage matrix 
alterations.[62] Understanding these HA-related modifications on cellular and molecular level 
may serve as a guide for the development of future therapies. Regardless of its mechanism of 
action, this natural polymer is prone to uncontrolled enzymatic degradation.[63] There are 
currently two types of HA available on the market, namely; low molecular weight (LMW) 
HA (0.5–3.6 million Da) and chemically crosslinked high molecular weight (HMW) HA (6.0 
million Da) hydrogels.[64] It has been reported that non-modified LMW HA has a half-life of 
only 10–13 h in osteoarthritic patients, while chemically modified HA hydrogels, such as 
hylan G-F 20, and genzyme can last for around 9 days.[65] The future viscosupplementation 
approaches need to have sufficient long-term action at the injection site for sustained efficacy. 
Moreover, several injections should be avoided to minimize infection risks and costs. For 
optimal treatment of an OA joint, the local environment of the entire joint needs to be reset to 
the physiological baseline.[63, 66] To this end, an injectable hydrogel approach that addresses 
the joint resurfacing, inflammation, and mechanical issues may offer a successful approach. 
1.3 Hydrogels 
 
Hydrogels are 3D crosslinked polymer systems capable of absorbing large amounts of water 
to form aqueous semi-solid gel networks.[67] They can be tuned with regard to their chemical 
nature, physical structure, sensitiveness to external stimuli, and biocompatibility.[68] They can 
be classified into different groups based on their:[69] 
⇒ crosslinks: physically or chemically crosslinked 
⇒ electric charge: ionic (charged) or neutral 
⇒ fate in the organism: degradable and slow-degradable 
⇒ origin: synthetic, natural, or hybrid 
⇒ responses to external effects: stimulus-sensitive and -responsive  
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 The term hydrogel as we know it today was first introduced by Wichterle and Lim in 
1960 for use as soft contact lenses.[70] Over the past decades, significant improvement has 
been made in designing and application of hydrogels as functional biomaterials including 
pharmaceutical,[71] biomedical,[71] and drug delivery systems.[72] The consistency (building 
blocks and concentration of physical or covalent crosslinking), degradability, and biochemical 
properties are important design criteria that can influence the structural, mechanical, and 
biological properties of the hydrogels initially and over time. In addition, the hydrogel 
building blocks must be stable[73] in either solid or solution form for storage prior to use. 
 Hydrogels are considered to be biocompatible in general due to their high water content, 
and low interfacial tension with the surrounding biological environment.[74] In some cases 
they even mimic the native ECM both compositionally and mechanically.[75] The swelling 
ratio, which has a major impact on the biological environment, depends on several factors like 
the osmotic pressure inside the hydrogel and the crosslinking density. For example, osmotic 
pressure can be changed with the deprotonation of carboxylic acids due to a pH change, 
whereas crosslinking density changes with the network degradation.[68]  
 A growing field for injectable hydrogels is the application in treatment of cartilage-
related diseases. Since they fit into any desired form, injectable hydrogels can match the 
usually observed irregular cartilage defects. This way, they might replace implantation 
surgeries in cartilage by minimal invasive injections.[76] A variety of chemical or physical 
crosslinking strategies can be used to form injectable hydrogels, but they must be carefully 
selected to match the specific application. For example, a suitable crosslinking rate is 
necessary for the proper formation of an injectable hydrogel in situ. If the gelation is too fast, 
premature gel formation in the syringe may occur, resulting in network defects that affect gel 
mechanical properties and can clog the syringe. On the other hand, if the gelation is too slow, 
precursors are likely to perfuse from the injection site into surrounding tissues, causing poor 
hydrogel properties and potentially an inflammatory response to unreacted monomers. 
Furthermore, the ability to form the hydrogel in the presence of living cells without 
interfering with native biochemical processes (bioorthogonal chemistry) is a key feature for 
cell biomedical applications.[77] Different approaches are available for the fabrication of such 
injectable hydrogels. Among them, click chemistry is the most researched chemoselective 




   
1.3.1 Injectable hydrogels for viscosupplementation in osteoarthritis  
The choice of material and appropriate fabrication method play crucial roles in developing 
ideal injectable hydrogels that can function as viscosupplement (lubricant) in OA. A variety 
of materials, both natural and synthetic, have been exploited to prepare injectable hydrogels 
for this purpose, leading to two main hydrogel categories; HA-based and non-HA-based 
hydrogels (Table 3). 
 
Injectable HA-based hydrogels for viscosupplementation in osteoarthritis 
To overcome the poor mechanical properties, fast degradation, and hydrolytic reactions of 
HA, this natural polymer is usually modified or combined with other materials.[79] In one 
approach, the HA backbone is derivatized with hexadecylic side chains, through amide bonds, 
with a 1–3 mol-% degree of substitution of repeating units, resulting in a stable hydrogel. 
HYADD4® forms a gel at a concentration of 0.3% (w/v) in PBS, using no chemical 
crosslinking.[80] Therefore, the biocompatibility and safety issues related to crosslinking 
techniques are eliminated. Hymovis® (8 mg/mL aqueous formulation of HYADD4®) has 
proven to be effective in reducing the signs and symptoms of pathology and in protecting 
cartilage in animal studies.[81] Recently Hymovis® has shown to be effective and safe for 
patients as well.[82] Furthermore, HA-based hydrogels can be designed for dual purposes; 
viscosupplementation and intra-articular drug delivery into joints (localize the curative 
constituent).[83] For example, recently Xia et al. showed that HA methacrylate can be photo-
crosslinked with chitosan microspheres encapsulating cordycepin (an inhibitor of ADAMTS-
5 and MMP13). This hydrogel ameliorated the progression of surgically-induced OA.[84] A 
crosslinked HA hydrogel in combination with dexamethasone reduces the toxicity of this 
drug.[85] In another study, a hyaluronat, chondroitin sulfate, N-acetyl-D-glucosamine 
compound in hydrogel form has shown more chondroprotective effects to rats' cartilage when 
compared to HA during the early stages of OA.[86] HA polymer grafted with antioxidant 
molecules led to a decrease in synovial membrane hypertrophy.[87] More examples can be 
found in Table 3.  
 
Injectable non-HA-based hydrogels for viscosupplementation in osteoarthritis 
Based on the knowledge of HA and HA-based hydrogel, researchers began to investigate 
other hydrogels with chemical and physical constructions resembling HA to extend the 
viscosupplementation effects. Recently in 2017, Milcovich and colleagues reduced the on-site 
enzyme degradation by optimizing a polysaccharide-based colloidal hydrogel. In this study, 
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zwitterionic vesicles were proposed as a physical crosslinker that caused the formation of a 
tunable network, offering a dual-therapeutic approach.[88] More examples can be found in 
Table 3. 
 





 Main components Advantages Ref. 
 
HA-based 
   
 Crosslinked HA  Providing drug delivery 
matrix for conjugate drugs 
[89] 
 Hexadecylic side chain 
derivative of HA 





 HA + cordycepin (inhibitor of 
ADAMTS-5 and MMP13). 
Inhibition of OA progression [84] 
 Hyaluronat, chondritin 
sulfate, N-acetyl-D-
glucosamine 
Chondroprotective effect [86] 
 HA+ dexamethasone Reduction of drug toxicity [85] 
 HA + antioxidant molecules Reduction of the synovial 
membrane hypertrophy 
[87] 
 HA + corticosteroid Rapid and long lasting pain 
relief 
[91] 
 HA + doxycycline Long-lasting drug agent 
Restoring the elastoviscosity 
[92] 
 Thioethyl ether derivative of 
HA 
Radical protective [93] 
 HA + chitosan Prevention of subchondral 
bone loss  
[94] 
Non-HA-based    
 Poly caprolactone + chitosan 
+ Etoricoxib (COX-2 
inhibitor) 
Reduction of drug toxicity 
Longer retention time 
[95] 
 Alginate + chitosan Reduction of the synovial 
membrane inflammation 






Reduction of on-site enzyme 
degradation 
[88] 
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Hydrogel formation by click chemistry 
Click chemistry is a term that was introduced by Sharpless et al. in 2001 to describe pairs of 
functional groups that rapidly and selectively react (click) with each other that give high 
yields without side-products and generally require no purification.[97] Due to its rapid 
crosslinking kinetics, high efficiency, unique bioorthogonality, and mild reaction conditions, 
click chemistry represents one of the most attractive classes of crosslinking chemistries for 
the formation of hydrogels with varying dimensions and patterns (Figure 4).[98] 
 
      
Figure 4. Preparation and potential biomedical applications of click hydrogels, microgels 
and nanogels.[98] 
  
 Among the different click reactions, the copper-catalyzed alkyne–azide reaction 
(CuAAC) is the most investigated method,[99] which is a [3+2] copper-catalyzed 
cycloaddition reaction between an azide and an alkyne to form a 5-membered triazole 
ring.[100] However, copper can be toxic, which limits its application in the biomedical field. 
To overcome this, Bertozzi et al. crosslinked cyclooctynes and azides by copper-free click 
chemistry using strain-promoted azide-alkyne cycloaddition (SPAAC) reactions, thereby 
eliminating the need of (metal ion) catalysts.[101] DeForest and Anseth showed that when a 
four-arm PEG is end-functionalized with difluorinated cyclooctyne, it can react with an azide-
functionalized crosslinker, via SPAAC. The ring strain and electron-withdrawing fluorine 
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substituents promote a rapid crosslinking reaction (~2 minutes) without a catalyst.[102] They 
were able to prove that the timescale and mechanism of the SPAAC reaction permits high 
viability (>95%) during encapsulation of both cell lines and primary cells. In another 
approach, Ito et al. reported the preparation of covalently crosslinked, degradable HA 
hydrogels using azide and cyclooctyne functionalized precursors (Figure 5).[89] 
 
            
Figure 5. In situ copper-free click reaction using strain-promoted 
hyaluronic acid precursors.[89] 
 
1.3.2 Polyethylene glycol and dendritic polyglycerol sulfate as building 
blocks for injectable in situ hydrogels 
 
Biocompatible natural polymers like HA mimic aspects of the native microenvironment, 
including its mechanical and biochemical properties for regulating cell adhesion, migration, 
and other key functions for tissue repair.[103] Nevertheless natural polymers possess batch-to-
batch variations, moderate yield through tedious processes,[104] and inferior mechanical 
properties. Furthermore, they are prone to uncontrolled enzymatic degradation.[105] To address 
these shortcomings, synthetic polymers have been frequently used for the design of injectable, 
cell-compatible hydrogels due to their commercial availability, low batch-to-batch variation, 
versatility for chemical modification, and therefore, the ease of tuning the mechanical 
properties of the resulting hydrogels. 
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Polyethylene glycol (PEG) 
PEG, a biocompatible polymer with a variety of biomedical applications,[106] is able to protect 
encapsulated cells from the host's immune response.[107]. PEG-based hydrogels have been 
successfully studied for the encapsulation of a broad range of cell types, including 
chondrocytes.[108] End hydroxyl functional groups of PEG could be substituted by other 
groups to obtain polymers for different applications. Accordingly, cyclooctyne could be 
attached to the end groups of PEG to obtain PEG-DIC.[109] This derivative of PEG is highly 
reactive and therefore a useful reagent for biocompatible copper free reactions,[110] where no 
active oxygen is generated as a result of copper salt addition.[111] 
 
Dendritic polyglycerol sulfate (dPGS) 
Dendrimers are highly branched, monodisperse macromolecules with well-defined structures 
which affect their physical and chemical properties.[112] Dendritic polyglycerol (dPG) is a 
hydrophilic, low-toxic branched polymer containing multiple hydroxyl (OH) groups on the 
periphery.[113] The hydroxyl groups can be easily functionalized and changed to other 
functional groups. This surface multifunctionality offers the opportunity for multivalent 
interactions with biological substrates[112] and thereby makes them valuable crosslinkers for 
preparation of multifunctional polymeric hydrogels.[114] In 2004, the Haag group developed a 
heparin mimetic sulfated branched polymer (dPGS) in one step by sulfation of dPG.[115] This 
dendritic fully synthetic analogue of heparin/heparan sulfate proteoglycans is a promising 
candidate to mimic ECM. The main advantages of dPGS over the other heparin mimetic 
scaffolds are high functionality, a gram scale and straightforward synthesis, as well as control 
over the degree of sulfation, which leads to an anti-inflammatory property and low 
anticoagulant activity.[115] dPGS showed inhibition of the complement system (C3a and 
C5a),[6] L-and P-selectin inhibition,[116] and inflammation targeting in an arthritis model.[117] 
Previously, Schulze-Tanzil and colleagues have demonstrated a chondroprotective and anti-
inflammatory potential of dPGS nanoparticles in the osteoarthritic knee joint suitable to 
suppress OA progression.[118] Following these results, it would be very interesting to use a 
dPGS-based hydrogel instead of nanoparticles for more resilience.  
 It is possible to crosslink dPGS-N3 units with PEG-DIC by a SPAAC reaction[119] to 
form an injectable hydrogel (Figure 6).  
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Figure 6. PEG-DIC and dPGS-N3 can be used as hydrogel blocks for in situ crosslinking by SPAAC to 
construct dPGS hydrogels.[120] 
 
 This reaction does not need any external stimuli/triggers for the initiation[121] and has 
proven to be cytocompatible in a previous study, in which human chondrocytes were 
encapsulated in dPGS-based hydrogels over 21 days.[57] The anti-inflammatory biological 
signals provided by sulfate groups to diminish an inflammatory processes can initiate the 
reparative processes and prompt the patient’s own tissue to complete its regeneration. The 
viscoelastic properties of such a hydrogel can be effectively tuned for a certain purpose by 
varying the molar ratio of the building blocks. Furthermore, this gelation procedure allows the 
in situ formation of hydrogels from injectable solutions. Unlike natural polymers, this fully 
synthetic hydrogel possesses superior mechanical properties and is not prone to uncontrolled 
enzymatic degradation since slowly-degradable linkers can be used in this approach. All these 
features make dPGS-PEG hydrogel superior to natural analogue and a good alternative for 
future approaches in OA viscosupplementation. 
1.4 In vitro investigation of potential treatments for OA  
 
Disease models are fundamental to advance research about the underlying causes of the 
disease, and for testing of potential therapeutics. Both in vivo[122] and in vitro[123] models for 
OA have been used in the past. In vivo models provide the most authentic reflection of the 
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whole-joint disease, but they are time consuming, expensive, and difficult to control. In 
contrast, in vitro models can be applied to examine novel therapeutic strategies in cartilage 
repair offering a cost effective analysis of potential substances in high throughput approaches 
under standardized conditions.[57] They attempt to mimic factors and conditions, which trigger 
OA or analyze the underlying pathways. Additionally, they offer the opportunity to study 
early features of the OA development that have been difficult to investigate due to the lack of 
available tissue from early disease and restricted molecular changes associated with it.[124] 
The ease of manipulating such systems, as well as a shift towards the 3R philosophy of 
refining, reducing, and replacing the use of animals,[125] make in vitro models attractive. Even 
though a great variety of in vitro models have been used by researchers, no consensus has 
emerged on the most appropriate model yet.[126] The relevance of in vitro models to actual 
disease needs to be carefully interpreted. For instance, some publications show the 
chondroprotective effects of glucosamine and chondroitin sulfate in in vitro models,[127] 
whereas clinical trials do not show such effects in vivo.[128] Although some of these 
differences can be attributed to delivery, complexity, duration, and variation of the phenotype, 
the in vitro models should be improved to better reflect the natural disease in vivo.  
 In vitro models can be categorized based on the trigger among which cytokine 
stimulation (cytokine-based) and load-based models are the most prevalent. The signaling 
pathways induced by cytokine- and load-based induction are similar in both models.[129] 
1.4.1 Load-based in vitro models 
 
Chondrocytes sense the loading of their environment through integrin receptors, which lead to 
cytoskeletal disruption and release of cytokines.[130] These cytokines then cause a release of 
enzymes, which cleave the ECM proteins. The degraded proteins are then capable of further 
induction of matrix degradation.[131] Static loading can induce changes and create an OA 
model when applied at an appropriate magnitude. Therefore, identification of the load 
thresholds that alter the balance from maintenance of homeostasis to catabolic degradation is 
important. For instance, static compression of calf cartilage to 25% or 50% strain for 24 h 
produces destructive alterations in cartilage metabolism, resulting in an over expression of 
MMP3, -9, and -13 and a decrease in COL2A1 and ACAN.[132] However, in such models, 
either the cytokine or the cytokine-producing cells should be added, otherwise the model 
cannot replicate inflammatory processes. Load-based models need extra operational 
equipment and set ups, which leads to limited applicability. Moreover, due to this limitation, 
the magnitude of experiments and thereby high-throughput readouts are usually impeded.  
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1.4.2 Cytokine-based in vitro models 
 
During OA, the increase in catabolic proteins is followed by stimuli such as cytokine or 
chemokine exposure, including IL-1β and TNF-α, which are present in the diseased joint.[133] 
Such cytokines represent ideal candidates for the induction of OA-like biological changes. 
Cytokine-based models are commonly used and generally well understood. The model is 
usually inexpensive and easy to manipulate. Cell expansion in vitro allows for a magnitude of 
experiments and therefore, testing multiple hypotheses and parameters from single sources of 
tissue is possible. Nevertheless, primary chondrocytes undergo dedifferentiation after only a 
small number of passages during which they lose their phenotype and their ability to form 
ECM.[134] IL-1β[135] and TNF-α[136] are the most commonly used cytokines in OA in vitro 
models. Other cytokines such as IL-6, IL-8, and VEGF play a role as well and are increased in 
the synovial fluid of OA joints.[133] However, they are hardly ever considered in model design 
because their production can be induced by other cytokines, such as IL-1β or TNF-α.[137]  
 The most commonly used in vitro models include ex vivo tissue culture (explants), 
monolayer culture, 3D culture, and co-culture. The advantages and disadvantages of some of 
these models are listed in Table 4.[126] 
 
Table 4. Advantages and disadvantages of some of the most commonly used in vitro models. 
Model type Advantages Disadvantages Ref. 
    
Monolayer   
culture 
Allows expansion from a 
single sample, investigation of 
distinct pathways in isolation  
Altered phenotype of isolated cells 
due to isolation from tissue and 
absence of normal ECM 
[138] 
Co-culture Considers cross-talk between 
cell types 
 
Altered phenotype of isolated cells 
Different cell types require different 
culture conditions, or a compromise if 
cultured together. 
[139] 
3D-culture Offers structure and force to 
sensitive cells 
Magnitude of force is scaffold 
dependent and may not reflect that of 
the normal tissue. 
Isolation and expansion of cell types 
are still required. 
[140] 
Explant Inexpensive, easily produced, 
cells maintained in normal 
ECM 
Cell death at cut edge of tissue, few 
replicates available from same source, 
more than one tissue type may be 
required to maintain viability, and 
physical attributes may change in 
culture.  
[141] 
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 In 2014, Schlichting et al. have introduced a scaffold-free in vitro OA model by using 
cells from porcine cartilage sources. They have thus developed an easy to manage OA model 
that mimics essential aspects of human chondrocytes and native cartilage biology, 
pathophysiology, and differentiation. In this model, 3D chondrocyte micromasses are cultured 
for 14 days to form ECM and then stimulated for further 7 days with TNF-α to introduce OA-
like changes, as well as the test substance (Figure 4). TNF-α addition established a 
degradative environment in line with the generation of macroscopic changes such as extensive 
proteoglycan loss as an implicit feature of human OA. Furthermore, gene expression profiling 
of porcine tissue-engineered cartilage micromasses revealed a human-like OA reaction pattern 
such as an extensive ECM loss (collagen type 2 (COL2A1), cartilage oligomeric matrix 
compound (COMP), aggrecan (ACAN)), cell death, formation of an inflammatory 
environment through the induction of genes coding for chemokines (IL-8, C-C motif 
chemokine 2 (CCL2)), OA-relevant enzymes (MMP1, -13), and the modulation of genes 
involved in skeletal development.[140] These typical OA changes can be examined and 
documented by conventional methods. Microscopically, OA cartilage is characterized by loss 
of collagen and proteoglycans[58] and these characteristics are analyzed in this model by 
collagen type II immune-staining and Safranin O staining, respectively. Further variations can 
be documented on gene expression level (Affymetrix porcine microarray and/or real time-











Figure 7. Schematic presentation of in vitro OA model. 
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2 Scientific goal 
 
Injectable hydrogels are a promising approach to treat cartilage damage induced by OA, 
which has been remained a major orthopedic challenge. The viscoelastic properties of such 
hydrogels can be effectively tuned for a certain purpose due to the molar ratio of the building 
blocks. The aim of this study is to investigate the potential of a slowly degradable dPGS-
based hydrogel as an alternative viscosupplement for OA management. Therefore, a 
characterization of the dPGS hydrogels that were newly developed in the Haag group should 
be carried out first. This includes, biological characterization, rheology measurements to 
determine a suitable concentration for intra-articular injections that mimics HA and a standard 
viscosupplement for OA, in terms of viscoelastic and mechanical properties. It also entails the 
potential underlying molecular and cellular changes and interactions with biological systems 
along with the hydrogel efficacy to alter the OA condition needs to be evaluated. This is 
possible by using in vitro OA-modeling, in regards to the parameters of cell viability, GAG 
content, collagen type II presence, and global gene expression profiling. Additionally, we 
compared the dPGS hydrogel with HA. The present conflicting data regarding the 
controversial effects of HA encouraged us to investigate more thoroughly the physiologic 
effect of HA on the cellular and molecular level, using the same unique in vitro model. 
Furthermore, understanding these HA-related modifications may create a better understanding 
of how intra-articular HA treatment could lead to therapeutic effects. 
                 







concentration for injection Physiological effects of HA 
Hydrogel efficacy to alter OA-like condition 
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In the following section the published articles are listed and the contributions of the authors 
are specified.  
3.1 Hydrolytically degradable, dendritic polyglycerol sulfate based 
injectable hydrogels using strain promoted azide–alkyne cycloaddition 
reaction 
Pradip Dey, Shabnam Hemmati-Sadeghi, and Rainer Haag, Polymer Chemistry 2016, 7, 
375-383.[119] 
https://dx.doi.org/10.1039/c5py01326g 
Figure 9. Covalent network formation by strain promoted azide–alkyne cycloaddition reactions. Adapted from 
reference [119]. 
In this publication, the author contributed to the acquisition, analysis, and interpretation 
of the biological data, and composed the related section in the manuscript. 
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3.2 Injectable hydrogels for treatment of osteoarthritis – A rheological 
study 
Benjamin von Lospichl,# Shabnam Hemmati-Sadeghi,# Pradip Dey, Tilo Dehne, Rainer 
Haag, Michael Sittinger, Jochen Ringe, Michael Gradzielski, Colloids and Surfaces B: 
Biointerfaces 2017, 159, 477-483.[142] 
# Authors contributed equally. 
https://doi.org/10.1016/j.colsurfb.2017.07.073 
The rheological properties of a slowy degradable dPGS hydrogel have been investigated to 
determine a suitable concentration for intra-articular injections. The oscillating and flow 
rheology showed an overall polymer concentration of 4.0 wt% dPGS hydrogels have similar 
viscoelastic properties to HA, the current standard viscosupplement for OA management. 
Figure 10. Rheology comparison between dPGS hydrogel and HA.[142] 
In this publication the author contributed to the concept, sample preparation, and 
rheology measurements, and composed parts of the manuscript. 
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3.3 TNF-induced biomimetic sulfated PEG-hydrogel inhibits proteoglycan 
loss and TNF-induced expression pattern in an osteoarthritis in vitro 
model  
Shabnam Hemmati-Sadeghi, Pradip Dey, Jochen Ringe, Rainer Haag, Michael Sittinger, 
and Tilo Dehne, Journal of biomedical materials research part B-applied biomaterials 2018. 
https://doi.org/10.1002/jbm.b.34139 
Figure 11. Viability and cartilage qualities.[120] 
In this publication the author contributed to the concept and experimental design, was 
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This study aimed to evaluate the potential of an anti-inflammatory PEG hydrogel for osteoarthritis (OA) management in an OA in vitro model.  Freshly isolated porcine chondrocytes were maintained high-density cultures to form cartilage-like 3D micromasses. Recombinant porcine tumor necrosis factor alpha (TNF-
α) was used to induce OA-like changes. Normal and OA-like micromasses were treated with dendritic polyglycerol sulfate-based PEG hydrogel. Live/dead staining showed that all micromasses remained vital and presented similar morphological characteristics. Safranin-O staining demonstrated a typical depletion of glycosaminoglycans in TNF-treated micromassbut not in the presence of the hydrogel. There was no distinct difference in immunohistochemical detection of type II collagen. Microarray data showed that rheumatoid arthritis and TNF signaling pathways were down regulated in hydrogel-treated OA-like micromasses compared to non-treated OA-like micromasses. The hydrogel alone did not affect genes related to OA such as ANPEP, COMP, CXCL12, 
PTGS2, and TNFSF10, but it prevented their regulation caused by TNF-α. This study 
provides valuable insights toward a fully synthetic hydrogel for the intra-articular 
treatment of OA. The findings proved the potential of this hydrogel to prevent the 
development of TNF-induced OA with regard to proteoglycan loss and TNF-α-induced expression pattern without additional signs of differentiation and inflammation. 
Keywords: microarray, hydrogel, dendritic polyglycerol sulfate, polyethylene glycol, tumor necrosis factor 




To date, no cure is available for Osteoarthritis (OA).1 In the end-stage, treatment options are restricted to total joint replacements. In early stages, symptom management is possible with nonsteroidal anti-inflammatory drugs (NSAIDs) or hyaluronic acid (HA) to relieve the pain, facilitate movement and slow OA progression.2 Due to the positive effects of intra-articular injections of HA (viscosupplementation) on pain relief, lubrication, and joint functional amelioration, their use is growing worldwide.3 HA exhibits unique viscoelastic properties with highly non-Newtonian characteristics that provide the synovial fluid with the friction-reducing fluid dynamic properties (lubrication), as well as resistance to compression and shear forces.4,5 Unfortunately it is prone to uncontrolled enzymatic degradation6 that substantially restricts the sufficient long-term action at the side of injection.  Synthetically derived hydrogels offer a highly tunable platform to create biomimetic 
environments that support repair of damaged or diseased cartilage7 or to deliver drugs.8 
Among them, dendritic polyglycerol sulfate (dPGS), which is a branded fully synthetic analog of heparin/heparan sulfate proteoglycans, is a promising candidate due to its high biocompatibility and presence of multiple sulfate groups on the periphery that act as an anti-inflammatory compound. dPGS has shown inhibition of complement system (C3a and C5a),9 L-and P-selectin inhibition,10 and inflammation targeting in an arthritis model.11 It is possible to cross-link dPGS azide (dPGS-N3) with polyethylene glycol-dicyclooctyne (PEG-DIC) to form an injectable hydrogel by a bioorthogonal strain-promoted azide–alkyne cycloaddition (SPAAC)12 reaction, that can be tuned with respect to its rheological properties. It has been shown that the dPGS-PEG hydrogel with an overall polymer 
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concentration of 4.0 wt% has the same viscoelastic properties as HA in the knee frequency range.5 Polyethlene glycol (PEG) is a biocompatible polymer that protects regenerative 
living cells from host immune response.13 PEG has been successfully studied for encapsulation of chondrocytes.14 All these features make dPGS-PEG hydrogel a good candidate for cartilage repair. In the present study, we investigated the potential of the 
dPGS-based hydrogel to alter the OA condition. In order to test the efficacy of our fully synthetic hydrogel, we used the porcine chondrocyte micromass culture model, which has been shown to be an alternative tissue platform for the evaluation of innovative substances and techniques for the treatment of OA.15 In this model, established normal micromass 
cultures were treated with dPGS-PEG hydrogel for 7 days under normal and OA conditions (by adding TNF-α.) Parameters such as cell survival, extra cellular matrix (ECM) formation or loss and changes in gene expression profiles were used to investigate the effect and to 
evaluate the potential to inhibit or alter the OA condition.15 
Materials and Method 
dPGS hydrogel formation: Basic components SO3pyridine complex and polyethylene glycol hydroxyl (PEG-OH) were used as received from company Fluka Production GmbH and Sigma Aldrich (Mn=6 kDa). PEG was further modified to homobifunctional polyethylene glycol-dicyclooctyne (PEG-DIC) and dendritic polyglycerol sulfate azide 
(dPGS-N3) at the Institute of Chemistry and Biochemistry of the Freie Universitaet of Berlin. These two macromonomeric components are capable of in situ crosslinking by strain-
promoted azide–alkyne cycloaddition (SPAAC) to construct dPGS hydrogels under physiological conditions, as shown in Figure 1.14,16 The components were prepared as solutions (2.5 wt%) in RPMI 1640 medium, and filtered through 0.2 µ filters (Sartorius) and 
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supplemented with 10% fetal bovine serum (FBS Thermoscientific, v/v), 100 U/mL penicillin and 100 µg/mL streptomycin (Biochrom) and 170 µM L-ascorbic acid (Sigma-Aldrich). The components were mixed in a 1:1 ratio and incubated at 37 °C for 60 min to form the hydrogel in situ.  
 
Fig 1: Schematic presentation of the polymer structure involved in the hydrogel formation. Polyethylene glycol-
dicyclooctyne (PEG-DIC) and dendritic polyglycerol sulfate azide (dPGS-N3) were used as macromonomers for in situ crosslinking by strain-promoted azide–alkyne cycloaddition (SPAAC) to construct dPGS hydrogels  
Chondrocyte isolation and preparation of 3D micromasses: Since the samples were obtained from a slaughterhouse, no animal approval was needed. Chondrocytes were isolated from medial and lateral femoral condyle cartilage of domestic pigs (9 donors) 
according to a previously published protocol.17 Briefly, cartilage slices were incubated for 
19 h in spinner flasks containing RPMI 1640 medium, supplemented with 10% fetal bovine 
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serum (FBS, Thermoscientific, v/v), 100 U/mL penicillin and 100 µg/mL streptomycin, 
333.3 U/mL collagenase II (all Biochrom), 1 U/mL collagenase P (Roche Diagnostics), and 
33.3 U/mL hyaluronidase (Sigma-Aldrich). Afterwards, incubated cell suspensions were strained through a nylon mesh with a 100 µm pore size (Becton Dickinson), washed in 
Hanks solution (Biochrom), and resuspended in a maintenance medium consisting of RPMI 
1640, 10% FBS, penicillin/streptomycin, and supplemented with 170 µM L-ascorbic acid (Sigma-Aldrich). Before preparing micromasses, cells from three donors were pooled together and three independent pools were created serving as biological replicates (n = 3). The high-density micromass culture (micromass), was described previously.15 Briefly, a 
volume of 200 µL containing 6*105 freshly isolated chondrocytes in maintenance medium was transferred to each well of 96-well flat bottom plates (Becton Dickinson). Micromasses were allowed to establish ECM for 14 days in all experimental groups and then were cultured for further 7 days under different conditions resulting in 4 experimental groups as following: (1) without stimulation (Ctr), (2) stimulated with 10 ng/mL TNF-α (R&D system) to induce OA-like changes (TNF), (3) treated with 2.5 wt% hydrogel in medium (Gel), and (4) treated with 2.5 wt% hydrogel in medium and 10 ng/mL TNF-α (GelTNF). 
Live/dead staining: Propidium iodide/fluorescein diacetate (PI/FDA) staining (Sigma) was performed to evaluate the cell viability of the micromasses. The micromasses were rinsed with phosphate buffered saline (PBS, Biochrom) and incubated for 15 min at 37 °C with 3 µg/mL FDA solution. After incubation, the micromasses were rinsed again with PBS and incubated with 100 µg/mL PI solution for 2 min at room temperature and under darkness. After an additional washing step, the micromasses were analyzed under a fluorescence microscope (Olympus AX70). As a result, living cells were green and the nuclei 
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of the dead cells red. 
Histological and immunohistochemical staining: In order to document ECM formation or loss, micromasses from all experimental groups that were cultured for a total of 21 days, were embedded in an optimal cutting temperature (OCT) compound (Sakura Finetek, Alphen aan den Rijn) and cryosectioned  at 8 μm. Cartilage-typical sulfated 
glycosaminoglycans (GAG) were stained with 0.7% Safranin O in 66% ethanolic solution, 
and cell nuclei were counterstained with 0.2% Fast Green in 0.3% acetic acid.  A histomorphometric analysis was performed to quantitatively determine the intensity of the Safranin O stain mainly as previously described.15 A pixel was counted as red ® if the 2-
fold of the red value was greater than the sum of green (G) and blue (B) (R-value×2>G-
value+B-value). Intensity was considered by correction (intensity=R×2−G−B) giving a scale from 0 to 510. The mean intensity (sum of intensities/area of interest) was calculated from each image. Collagen type II expression was analyzed by immunohistochemistry with polyclonal mouse anti-porcine type II collagen antibodies (Calbiochem CP18). Mouse IgG (DAKO) served as 
control. EnVision detection antibody was used to visualize collagen type II antibodies and 
nuclei were counterstained with hematoxylin (DAKO). Stainings were photodocumented using a light microscope (AX 10, Zeiss) with a SpeedXTcore 5 (JENOPTIK) camera and ProgRes®  Capture Pro version 2.6 software.  
RNA Isolation: For each biological replicate (n = 3) of each experimental group, total RNA was isolated from micromasses that were cultured over 21 days. 5 micromasses were snap-
frozen and stored at −80 °C. Frozen samples were transferred to 1ml TriReagent (Sigma-
Aldrich) and mechanically homogenized. Subsequently, 133 µl 1-bromo-3-chloro-propane 
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(Sigma-Aldrich) was admixed followed by centrifugation for 45 min at 13,000 g. The 
aqueous phase was collected and supplemented with same volume of 70% ethanol. Further purification was performed according to a protocol for animal tissues of the RNeasy Mini 
Kit (Qiagen). The RNA concentration was determined by using the Nanodrop 1000 spectrophotometer (Thermo Scientific). The integrity of the RNA was determined by using 
Agilent Bioanalyzer 2100 (Agilent). The RNA samples used in this study contained an 
integrity number (RIN) above 8.9. (Supplementary Table 1) 
Affymetrix GeneChip porcine genome array profiling: In total, data from 12 microarray experiments (4 groups in triplicates) are included in this study. A total of 23,937 probe sets representing 20,201 porcine genes were included in the Affymetrix GeneChip porcine array 
(Affymetrix). The RNA processing and hybridization were performed according to the 
manufacturer’s protocol. The gene chips were scanned with the Affymetrix GeneChip 
Scanner 3000 (Affymetrix). Raw gene expression data were normalized and analyzed with the GeneChip Operating Software 1.4 (GCOS, Affymetrix). Comparisons between triplicates of the Ctr and TNF groups were performed on the basis of a pre-published markers associated with the in vitro OA model (9 comparisons).15 Other paired group comparisons 
were performed between replicates of each group. Genes were considered as differentially 
expressed genes (DEGs) and selected for further analysis that showed 1) a significant signal change, which was detected by GCOS for at least 7 out of 9 comparisons, 2) an analysis-dependent mean-fold change, and 3) a p-value < 0.05 applying t-test. K-mean clustering 
(KMC) and hierarchical clustering (HCL) analysis were performed with normalized log 2-transformed signals. A Pearson correlation was done to determine the distance measure and the average linkage clustering by agglomeration rule using Genesis 1.7.6 software.18 A 
48
 9 
principal component analysis (PCA) was carried out with ClustVis19 to determine similarities and differences of the gene expression pattern of each experiment in comparison to other cell signatures obtained from the public database. In this study, Gene 
Ontology (GO) terms, biological process (BP) function enrichment analysis, and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs were performed based on the Database for Annotation, Visualization, and Integrated Discovery (DAVID).20 In order to find the names for unnamed porcine probe set IDs, we used cross-species relationships between porcine and human probe set IDs 
(U133PlusVsPorcine_Complex sheet) in combination with human NetAffx annotation file 
(HG_U133_Plus_2 Array, Affymetrix).  
Statistical Analysis: The intensity of the Safranin O stained areas are indicated as the mean intensity of 3 biological replicates and the respective standard deviation. The significance 
level of log 2-tranformed microarray data was determined with the independent two sample t-test statistics of the Excel 2011 software package (Microsoft, Redmond). The normality distribution was investigated applying the Anderson−Darling test21 and the equal 
variance of the compared sample groups was tested applying the f test.22 For normal 
distributed data with equal variance, the t-test was applied, while the Mann-Whitney rank sum test was used for data that failed normality testing. Differences were considered 
significant at P < 0.05. 
Results 
1. Cartilage qualities of the model 
1.1 Viability and ECM formation. All experimental groups remained vital and presented similar morphological characteristics (round-shaped cells and homogenously dispersed) at 
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day 21 (Fig 2, A-D). As expected, the Safranin-O staining showed less accumulation of GAGs in “TNF” but unexpectedly not in ''GelTNF'', which suggested that TNF-α did not deplete 
GAG in the presence of hydrogel (Fig 2, E-H). Histomorphometric analysis confirmed that 
GAG was significantly lower in ''TNF'' than in other groups (Fig 3).  
 
Fig 2 Viability and cartilage qualities. (A-D) Live-dead staining of micromasses after 21 days. Depicted are the live-dead 
staining of micromasses in 4 previously described groups. Living cells were stained green using FDA; dead cells were stained red using PI. (E-H) Safranin O staining documented the proteoglycan content orange. (I-L) Immunohistochemistry demonstrated the presence of cartilage-specific collagen type II (red) as a component of the formed matrix. Scale bar represents 200 μm. 
Since our histomorhomometrics of GAGs are less accurate at high intensity staining areas 
and the microarray data did not show any induction of GAG-related gene expression such as ACAN, COMP and HAPLN1, we only focused on differences correlated to TNF group. There was no distinct difference in immunolabeling for type II collagen when the normal and TNF-





1.2 Gene expression profiling. In order to gain insight into the hydrogel effect on OA, genome-wide Affymetrix microarray gene expression profiling was performed. To get an idea of the consistent expression alterations that replicated the established OA in vitro 3D model, we did a comparative analysis of OA-related genes in TNF-α-induced and non-induced cultures. Consistent expression alterations achieved through TNF-α treatment were found in the groups mentioned in table 1. More than 85% of genes, which were differentially regulated in TNF-α-induced micromass cultures compared to non-induced cultures, showed the same trend as presented in the literature (Table 1).15      
Fig 3 Histomorphometrical analysis. Histomorphometric analysis of Safranin O stainings of all the experimental groups at day 21 considering the proportion and intensity of the stained area as mean intensity (n=3). 
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Table 1 Genes differentially regulated in TNF-induced cultures (TNF) compared to non-induced cultures (Ctr). 
For signal values, see the Supplementary Table 2 in the Supporting Information; bold = consistence of increase or 
decrease with OA in vitro reference, underlined = controversial to OA in vitro reference, italic = no significant detection. FC = Fold Change. 
Gene Symbol       FC Gene Symbol              FC Gene Symbol FC Inflammation  Transcription 3.40 Enzymes  PTGS2 11.40 WIF1 -24.82 ADAM10 1.22 
TAC1 -19.55 DLX5 -8.25 MMP13 6.65 
VCAM1 6.81 TWIST1 3.40 MMP2 1.46 
PTX3 -5.16 MAFB 2.81   LY96 3.13 ELL2 -3.35 Miscellaneous  VLDLR 1.22   C1orf54 47.03 CEBPD 2.99 ECM components SOD2 17.15 
CEBPB 3.94 COL9A2 -10.97 RCAN2 1.03   COL2A1 -25.79 ABRACL 2.79 Cytokines  CILP 7.94 GGTA1 2.60 CCL2 70.20 THBS3 -4.59 MYLK 3.82 
CXCL8 55.72 HAPLN1 -9.48 SNX10 11.40 
CXCL12 18.95 COMP -8.64 MAP3K8 4.03 
CXCL2 16.76 LUM -1.48 THY1 -1.21 
CXCL14 -1.16 NID2 -5.66 S100A4 3.46     SAMD9 5.49 Cell death  Signaling  B4GALT5 9.55 TNFSF10 2.74 RGS5 -100.04 DUSP6 3.01 
PMAIP1 11.58 ADGRA3 -2.68 BASP1 2.14 
AHR  5.61 MARCKS 1.55 ALDH1L1 7.02 
HMOX1 1.95   APOD -11.67 ADM 5.61 Growth factors  SLC25A37 6.40   IGFBP3 4.19 PHLDB2 2.48 Proliferation/differentiation IGFBP6 -2.18 GLIPR1 2.87 
PTN -6.30 ZMAT3 1.85 GUCY1B3 1.94 
ID4 -13.93 TGFBI -2.68 NCAM1 -4.74 
NUAK1 3.97   UGCG 5.97   Enzymes  MSN 2.56 Skeletal development MMP1 13.00 WWP2 -2.79 
GPNMB 3.59 CTSC 16.76 NAP1L2 -8.84 
FRZB -23.70 ANPEP 7.64 LIFR 3.91 
CLEC3B -26.81 CTSS 4.06 SM22A 1.09 
RUNX1 1.77 PDK4 -8.25 RAI14 2.41 
ITGB8 2.48 HTRA1 2.89 MARCH3 3.43 
CDH11 3.79 PLK2 3.70 PDLIM1 1.38 
HOXA3 -5.16 MMP3 17.82 SLA-1 3.65 
MAMDC2 3.40 FAM108C1 1.70   
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2. Comparison of gene expression pattern 
2.1 HCL. HCL gene analysis of all the possible intra- and inter-group comparisons between the groups with fold changes of > 2 or < -2 was performed to check for consistency of the biological replicates and to identify similarities of the expression pattern. The HCL displayed the closest pattern similarity between biological replicates demonstrating reproducibility of the experiment as well as homogenous experimental groups (Fig 4, A). HCL disclosed two distinct clusters, one with only the TNF-α-treated group and another cluster including the Ctr and hydrogel-treated groups. 
 
Fig 4 HCL and K-mean clustering. Samples illustrated from left to right are Ctr, TNF, Gel, and GelTNF.   
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2.2 K-mean clustering. Genes from inter-group comparisons were used for k-mean clustering. The selected 1521 differentially expressed genes (DEGs) (fold change > 3) were 
analyzed using Genesis. This resulted in five unique clusters illustrating the genes decreased in TNF (cluster 1); downregulated in Ctr and marginally upregulated in GelTNF 
(cluster_2); downregulated in Gel and GelTNF (cluster_3); upregulated in Ctr and downregulated in TNF-induced (cluster_4); and upregulated in TNF and marginally 
upregulated in GelTNF with a smaller signal altitude (cluster_5) were predicted. (Fig 4, B-F) (Supplementary Table 3). In favor of gaining further insight into molecular functions (MF) 
related to hydrogel the GO MF terms analyses were conducted for functional annotation of the DEGs in cluster 3. The top 10 GO MF terms are presented in Table 2. The results demonstrated that the selected genes were significantly enriched in functions mainly associated with bindings i.e., ATP binding (23 genes), and calcium ion binding (20 genes). Concerning pathways associated with TNF-α, which could be impeded by the presence of 
hydrogel, the KEGG pathway database was searched using the genes from cluster 5. The analysis demonstrated 15 pathways that showed a significantly different expression in TNF and GelTNF compared to Ctr and Gel. Five of the most significantly different expressed pathways are listed in Table 2 e.g. rheumatoid arthritis, and TNF signaling pathway.       
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Table 2 GO MF terms and KEGG pathways. The top 10 GO MF terms (sorted by the number of genes) associated with 
cluster 3 and KEGG pathways  (sorted by p-value) related to cluster 5. 
GO Accession Name No. of enriched genes (gene symbol) P-value 
    
GO:0005524 ATP binding 23 (KIF23, CDK1, KIF4A, KIF11, NEK2, 
KIF15, STK17B, AURKA, PBK, MCM2, 
UBE2C, MCM3, CKB, DMPK, ACTG2, PLK1, 
PAK1, CIT, ORC1, TOP2A, MELK, MYLK, 
KIF20A)  
1.20E-02 
GO:0005509 calcium ion binding 20 (S100A4, FKBP9, BMP1, MASP1, 
ENPP2, EFEMP2, MYL1, S100A10, SLIT2, 
CDH13, SULF2, GSN, NUCB2, FKBP14, 
VCAN, AGRN, ADAM8, RCN3, MELK, VLDLR)  
1.50E-05 
GO:0004674 protein serine/threonine 
kinase activity 
9 (PLK1, STK17B, AURKA, PBK, PAK1, 
CIT, MYLK, MELK, DMPK)  2.70E-03 
GO:0003682 chromatin binding 7 (CDK1, LOC100623233, 
LOC100514810, CKS2, ORC1, TOP2A, CDCA5)  
9.10E-02 
GO:0004252 serine-type endopeptidase 
activity 
6 (MASP1, RHBDL1, HTRA3, PRSS23, 
PRSS35, PLAU)  2.00E-02 
GO:0031418 L-ascorbic acid binding 5 (P3H2, P3H1, P3H3, PLOD1, EGLN3)  4.80E-05 
GO:0005201 extracellular matrix 
structural constituent 
5 (COL3A1, COL1A2, VCAN, COL5A2, COL5A1)  4.80E-04 
GO:0005506 iron ion binding 5 (P3H2, P3H1, P3H3, PLOD1, EGLN3)  6.40E-02 
GO:0019901 protein kinase binding 4 (CKS2, AURKA, THY1, KIF20A)  3.00E-03 
GO:0003777 microtubule motor activity 4 (KIF23, KIF4A, KIF15, KIF20A) 1.90E-02     
KEGG ID Pathway term No. of enriched genes (gene symbol) P-value 
    
ssc05323 rheumatoid arthritis 12 (IL6, JUN, IL18, CSF1, VEGFA, CXCL8, IL-6, ANGPT1, CCL5, MMP3, CXCL12, MMP1)  
3.90E-07 
ssc04623 cytosolic DNA-sensing 
pathway 
10 (DDX58, IL6, IL18, IRF7, TREX1,  IL-6, IL33, CCL5, CASP1, ZBP1)  1,40E-06 
ssc05164 influenza A 15 (XPO1, IL6, IL18, IL-6, CXCL8, RSAD2, OAS1, IL33, CCL5, IRF9, DDX58, JUN, IRF7, CASP1, MX1)  
1.90E-06 
ssc04668 TNF signaling pathway 10 (VCAM1, CFLAR, TRAF2, IL6, PTGS2,  JUN, CSF1, IL-6, CCL5, MMP3)  1.50E-04 
ssc04060 cytokine-cytokine receptor 
interaction 
14 (IL6, CSF1, IL18, LIFR, IL-6, CXCL8, CCL19, CD40, CXCL11, CCL5, CXCL12, 
CXCL13, CXCL16, VEGFA) 1.90E-04 
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2.3 PCA. For allocating the hydrogel effects in regard to the different processes mentioned in Figure 5, the expression pattern of several tissues (fat, bone, cartilage) in vitro cultures (monolayer chondrocytes, fibroblasts) and conditions (normal, OA) obtained from public databases were used. In the first 5 PCA analysis the distance between our 4 experimental groups was rather low compared to the reference signatures suggesting no similarities towards any particular cell type or mechanism, namely adipose, fibroblast, bone, redifferentiation, and dedifferentiation (Fig 5, A-E), except for OA signature (Fig 5, F). TNF 
and GelTNF were shown to have closer expression profile to OA signature, although GelTNF was less pronounced than TNF, whereas Ctr and Gel groups revealed common characteristics with normal cartilage (Fig 5, F). Since we only observed differences between experimental samples in the OA signature, we further focused on genes associated with OA.   
 
Fig 5 Principal component analysis of different cell signatures. Red = Ctr, blue = Gel, green = GelTNF, and yellow = TNF, PC=Principal Component. Ind=Induced. h=human. P=Passage. 
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2.4 OA signature. 65 from 92 OA-related genes (Table 1) that had a signal difference greater than 1.4-fold were chosen to follow the OA state of experimental groups throughout the study. A gene expression analysis of normal and OA micromass treated with hydrogel 
resulted in 3 different sets of gene groups (Fig 6): A) Genes that were regulated by TNF-α and their expression could be altered by adding hydrogel (GelTNF) more toward normal conditions. 72% of genes were categorized in this group, e.g., MMP13, CXCL8, TNFSF10, 




Fig 6 OA marker gene expression. X-axis represents log2-transformed signals of all experimental groups including: Ctr 
(purple), TNF (green), Gel (red) and GelTNF (blue). 
Discussion 
This study was undertaken to investigate whether OA-cartilage can benefit from a fully synthetic dPGS hydrogel. Synthetic hydrogels offer a highly tunable platform to create 
biomimetic environments that support repair of degenerated cartilage. The Haag group has 
synthetized a heparin-analogous highly sulfated dendritic polymer dPGS that mimics highly 
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polyanionic GAGs.23,24 Until now, dPGS has shown anti-inflammatory properties e.g. L-and P-selectin inhibition, reduction of compliment activation compared to heparin,10,24 and inflammation targeting in vivo.11 The main advantages of dPGS over the other heparin 
mimetic scaffolds is the easy control over the degree of sulfation, facile access to the 
functional groups on the dPG surface and low anticoagulant activity.23 Here we crosslinked 
dPGS with PEG by strain promoted azide-alkyne cycloaddition (SPAAC) reaction which does not need any external stimuli/triggers for the initiation25 and was proven to be 
cytocompatible in our previous study where human chondrocytes were encapsulated in 
dPGS-based hydrogels over 21 days.16,24 Furthermore, this gelation procedure allowed the formation of hydrogels in situ from injectable solutions. Unlike natural polymers our fully synthetic hydrogel does not possess inferior mechanical properties and is not prone to 
uncontrolled enzymatic degradation since we used slow-degradable linkers in this 
approach. dPGS hydrogels were evaluated in the present study for applications in OA 
prevention, through characterization by an in vitro OA model.  To overcome the limited 
availability of human primary tissues we used a porcine in vitro OA model that has been 
proven by the Sittinger group as suitable tissue platform for a long-term evaluation of 
innovative substances for the treatment of OA.  A 3D culture is essential for a chondrogenic phenotype in vitro since the phenotype of differentiated chondrocytes is unstable in culture26 and lack of the cell-cell and cell-ECM interactions in monolayer cultures results in a phenotypic and functional chondrocyte dedifferentiation.27 This setup overcame the above-described issues. In our 3D cell cultures chondrocytes were less likely to dedifferentiate because of their greater cell motility, synthesis of ECM, and the physiological release and storage of bioactive molecules such as 
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cytokines.  On the other hand, since the hydrogel is added to the 3D micromasses at the same time as OA-mediator, the hydrogel effect could be considered preventative rather than 
regenerative. Even though a total polymer concentration of 4.0 wt% is appropriate for intra-articular injection in terms of viscoelastic properties, we had to further dilute this concentration to 2.5 wt% to make the medium change feasible, which is a common way for testing viscous substrates such as HA in vitro.28 
Live-dead staining of micromasses revealed a majority of viable cells embedded in ECM after 7 days of treatment with hydrogel in normal and OA conditions. We found that the cells were evenly distributed through matrix in all the experimental groups with a normal morphology. This confirms previous findings and suggests that dPGS is not harmful in 
different cell types and even in vivo29-31 and is in line with numerous studies that shows PEG 
hydrogels provide a unique niche for cell encapsulation, as they are highly biocompatible to the cells under the proper polymerization conditions.32,33 The micromasses undergo several changes that are broadly characterized when treated with TNF-α. Following the changes reported in the literature by Schlichting and colleagues we observed a clear depletion of 
proteoglycans in TNF as well, but surprisingly almost no proteoglycan depletion in GelTNF. Proteoglycan depletion plays a major role in the histopathological assessment of OA grade34 and is a detectable feature in this model. Following this line of thought, our results showed an inhibition effect caused by the hydrogel that prevented TNF-α from significantly reducing proteoglycan in the ECM of a micromass culture. We assume one or more of the following mechanisms are responsible for this action; TNF-α absorption by the dPGS hydrogel, destruction of the TNF-α structure by dPGS hydrogel, and/or activating counter-
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mechanism by dPGS hydrogel. However, the mechanism behind is subject of further 
investigatigation. Collagen type II immunostaining did not reveal any specific differences between experimental groups. This observation was in line with the previous data regarding this model that claimed the total collagen loss was not too pronounced and that it was reproducible, as could also be observed in the proteoglycan measurements. In order to make sure that our 3D culture served as an OA model shown in our previous work, gene expression profiles that contain clusters that have been shown to play fundamental roles in 
in vitro OA model have been investigated. We observed more than 85% consistency with 
our previous work when comparing the TNF-α-induced group with the control, which 
proves that our model has very good reproducibility. The 15% difference can be explained due to donor-specific differences and the shorter experimental time frames.  Hierarchical clustering analysis demonstrated that replicates of TNF group were assigned to a separate main cluster group, whereas the GelTNF replicates were reproducibly 
categorized into an independent group with Gel and Ctr. This suggests that hydrogel could shift TNF-α-induced effects toward normal conditions ("Ctr"). Further investigation through genes regulated by hydrogel, revealed significant binding functions, namely, ATP binding, calcium ion binding, protein serine/threonine kinase activity, chromatin binding, serine-type endopeptidase activity, L-ascorbic acid binding, extracellular matrix structural constituent, iron ion binding, protein kinase binding, and microtubule motor activity. This 
can be explained due to dPGS's anti-inflammatory properties that play a crucial role in 
multivalent charge-mediated interactions, and binding events between multivalent polymer and biological targets.11,35,36 Such bindings can be explained by nonspecific and electrostatic interactions of the anionic functionalities with basic amino-acid residues of the collagen 
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matrix or other biological targets, for example, side chains of lysine or arginine.31 Another 
interesting observation was made when assigning differentially expressed genes (DEGs) in TNF-α-treated groups to KEGG pathways resulting in pathways like rheumatoid arthritis 
(IL6, JUN, IL18, CSF1, VEGFA, CXCL8, IL-6, ANGPT1, CCL5, MMP3, CXCL12, MMP1), and the TNF-signaling pathway (VCAM1, CFLAR, TRAF2, IL6, PTGS2, JUN, CSF1, IL-6, CCL5, MMP3). As shown in Figure 4 (cluster 5), these DEGs were upregulated in TNF and only marginally 
upregulated in GelTNF. These findings further confirm the inhibitory effect of the hydrogel on TNF-α efficacy mentioned earlier.  
Previously, we demonstrated the chondroprotective and anti-inflammatory potential of 
dPGS nanoparticles in the osteoarthritic knee joint that were suitable to suppress OA progression.37 Following these results, we investigated a dPGS-based PEG-hydrogel with tunable mechanical properties for OA alteration in this study,   
Expression pattern of several tissues (fat, bone, cartilage) in vitro cultures (monolayer chondrocytes, fibroblasts) and conditions (normal, OA) were used to classify the effect of 
the Gel on normal and TNF-α-stimulated chondrocytes in regard to processes associated with de-, re-, osteogenic, chondrogenic, osteoarthritic, fibroblastic differentiation. None of the signatures demonstrated any differences between our experimental groups except for OA signature. PCA of OA-related genes demonstrated, that the TNF-α signature was most similar (shortest distance) to the OA gene expression pattern and the addition of dPGS-hydrogel (GelTNF) shifted the pattern towards the pattern of healthy native chondrocytes, which further confirmed the inhibitory effect of the hydrogel on OA. The effect of the hydrogel on the normal condition (Gel) was similar to the control (Ctr), which demonstrated that the hydrogel itself was not harmful to normal micromasses and could be 
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considered the same as the control group. Following the comparison of OA-related gene expression from porcine microarrays, 3 potential gene groups were identified (Fig 6). Among the 47 genes involved in group A, 21 genes such as C1orf54 (FC=-31.27), CXCL12 (FC=-11.06), PTGS2 (FC=-7,7), and COMP (FC=6,5) were regulated significantly different 
(with FC>2) in GelTNF in comparison to TNF, whereas no significant change was observed 
between Gel and Ctr. This suggested that hydrogel alone did not affect these genes but it could prevent their regulation from TNF-α effect. C1orf54 is relatively unknown protein with no literature available regarding its function, or expression in different cell types or disease models. Lu et al. showed that the CXCL12/CXCR4 axis played a pivot role in 
aggrecanase activation and cartilage degradation.38 The observed down regulation of CXCL through hydrogel could also lead to inhibition of the CXCL12/CXCR4 signaling axis and slow down the aggrecanase-mediated catabolic processes and diminishes the pathological progress of osteoarthritis. Increased expression of PTGS2 (COX-2) has been reported in 
cartilage and synovial tissues from patients with OA.39 Lopez-Armada et al. demonstrated the induction of PTGS2 (COX-2) expression in chondrocytes by adding TNF-α.40 Since 
PTGS2 is responsible for elevated production of lipid mediators including prostaglandins 
such as PGE2 in the OA joint,39 this hydrogel, which serves as an inhibitor to this mediator, may potentially be used for treatments in the future. COMP is a cartilage matrix protein that stabilizes ECM via specific interactions with matrix components such as collagen, aggrecan and fibronectin. Its degradation may be an index for early OA diagnosis and related to the 
severity of OA.41,42 In our study, the COMP degradation was compensated after hydrogel treatment.  ANPEP is a broad specificity aminopeptidase. Balakrishnan et al have detected 
ANPEP in the synovial fluid of OA patients.43 Rao et al. explored the interaction between OA-
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related genes and demonstrated ANPEP role together with MME, CTH, BCAT2, TST, ELTD1, and TNN in one protein-protein interaction network.44  In conclusion, the present study provides valuable insights towards a new fully synthetic 
dPGS-based hydrogel for the intra-articular treatment of OA. These findings demonstrated the potential of the hydrogel to prevent the development of TNF-α-induced OA with regard to proteoglycan loss and a TNF-α-induced expression pattern without additional signs of 
differentiation and inflammation. The diverse potencies (injectable, anti-inflammatory, lubricant, etc.) of this hydrogel can contribute to protect OA joint and encourage further 
investigation towards a new alternate for viscosupplements in human OA management. 
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Abstract: The aim of this study is to identify gene expression profiles associated with hyaluronic 16 
acid (HA) treatment of normal and osteoarthritis (OA)-like tissue-engineered cartilage. 3D 17 
cartilage micromasses were treated with tumor-necrosis factor-α (TNF-α) (OA-inducer) and/or 18 
HA for 7 days. Viability was examined by PI/FDA staining. To document ECM formation, 19 
glycosaminoglycans (GAG) were stained with Safranin O, and cartilage-specific type II collagen 20 
was detected immunohistochemically. Genome-wide gene expression was determined using 21 
microarray analysis. Normal and OA-like micromasses remained vital and showed a spherical 22 
morphology and homogenous cell distribution regardless of the treatment. There was no distinct 23 
difference in immunolabeling for type II collagen. Safranin-O staining demonstrated a typical 24 
depletion of glycosaminoglycans in TNF-α-treated micromasses (-73%), although the extend was 25 
limited in the presence of HA (-39%). The microarray data showed that HA can influence the 26 
cartilage anabolism via stabilizing the chondrocyte phenotype (MMP3 downregulation) in 27 
pathological conditions. The upregulation of VEGFA and ANKRD37 genes supports the 28 
chondroprotective role of HA. The results of this study validate the feasibility of the in vitro OA 29 
model for the investigation of HA. On the cellular level no inhibiting or activating effect of HA 30 
was shown. Microarray data demonstrated a minor impact of HA on gene expression level. 31 
Keywords: hyaluronic acid; osteoarthritis; in vitro model; microarray 32 
1. Introduction 33 
Hyaluronic acid (HA) is a main component of articular cartilage, which provides the backbone 34 
of large proteoglycan complexes. Moreover, HA endows synovial fluid with its viscoelastic 35 
properties and thereby provides lubrication for the articular surfaces [1]. HA binds to a cluster of 36 
differentiation 44 (CD44) receptors, and this binding inhibits interleukin (IL)-1β expression and 37 
leads to a decline in matrix metalloproteinase (MMP) -1, 2, 3, 9, and 13 production [2]. As 38 
osteoarthritis progresses, natural HA concentration alters towards lower ranges of HA molecular 39 
weight, which deteriorates the mechanical/viscoelastic properties of the synovial fluid [3]. 40 
Intra-articular HA administration has aimed to restore these properties [4], although there is 41 
controversy over its underlying attributes. Apart from shock absorption and joint lubrication, some 42 
proposed therapeutic mechanisms of HA action in the OA joint are chondroprotection, 43 
proteoglycan synthesis, and anti-inflammatory effects [5]. The proposed mechanisms and their 44 
controversial discussion encouraged us to investigate the manifold effects of HA on 45 
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tissue-engineered cartilage on the cellular and molecular level. Our general aim is to create a better 46 
understanding of how intra-articular HA treatment could provide therapeutic effects. 47 
In order to address this question we used an established in vitro OA model which offers a 48 
high-throughput analysis of potential active substances in a reproducible and very well 49 
characterized approach under standardized conditions [6, 7]. In 2014, Schlichting et al. overcame 50 
the low availability of human primary tissue and disadvantages of animal models by using cells 51 
from porcine cartilage sources. They thus developed an easy to manage OA model by introducing 52 
tumor necrosis factor α (TNF-α) into a 3D-micromass culture, which has already been shown to 53 
mimic essential aspects of human chondrocyte and native cartilage biology, pathophysiology, and 54 
differentiation. TNF-α addition established a degradative environment in line with the generation 55 
of macroscopic changes such as extensive proteoglycan loss as an implicit feature of human OA. 56 
Furthermore, gene expression profiling of porcine tissue-engineered cartilage micromasses revealed 57 
human OA reaction pattern such as extensive ECM loss (collagen type 2 (COL2A1), collagen type 9  58 
(COL9A1), cartilage oligomeric compound (COMP), aggrecan (ACAN)), cell death, formation of an 59 
inflammatory environment through the induction of genes coding for chemokines (interleukin 60 
(IL8), C-C motif chemokine 2 (CCL2)), and OA-relevant enzymes (matrix metallopeptidase 1, -13 61 
(MMP1, -13)), and the modulation of genes involved in skeletal development [7].  62 
To study the effects of HA on cartilage formation and maintenance, 3D chondrocyte 63 
micromasses were cultured for 14 days to form extracellular matrix (ECM) and were stimulated for 64 
further 7 days with HA under normal and OA-like conditions (by adding TNF-α). Parameters such 65 
as cell survival, ECM formation, or changes in gene expression profiles were used to evaluate the 66 
physiologic action of HA on the cellular and molecular level. 67 
 68 
2. Results 69 
2.1. Effect of hyaluronic acid on chondrocyte viability and extracellular matrix formation 70 
To examine the HA effect on normal and OA-like tissue-engineered cartilage on cellular level 71 
we obtained fluorescent images from the live/dead assay which demonstrated that all 72 
tissue-engineered chondrocyte micromasses in this study remained vital. (green; Figure 1A-E). 73 
Furthermore, the images showed a homogenous distribution of chondrocytes within the ECM and 74 
displayed a spherical morphology of cells over a period of 21 days throughout the culture 75 
conditions (Figure 1A-E). Immunohistochemical staining of cartilage-characteristic collagen type II 76 
revealed the secretion of this protein as a component of the formed matrix in 3D cartilage 77 
micromasses after 14 days (starting point), and after 7 days stimulation with TNF-α or treatment 78 
with HA regardless of the combination with TNF-α (Figure 1F-J).  79 
During culture, micromasses have developed an ECM rich in proteoglycans at day 14 (starting 80 
point), histologically detected by Safranin O staining (Figure 1K). Afterwards micromasses were 81 
treated for further 7 days with TNF-α alone or with HA under normal and OA-like conditions, 82 
where the addition of TNF-α expedited OA pattern-oriented changes including GAG depletion. 83 
The histological sections from these samples showed less accumulation of GAGs in TNF-α-treated 84 
groups with marginal increase in HyaTNF in comparison to TNF-α (Figure 1L-O). HA alone led to 85 
a non-significant increase of GAG.  86 
  87 
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The histomorphometric analysis further confirmed that GAGs were significantly lower 114 
secreted in TNF-α-treated groups and HA did not lead to any significant alterations (Figure 2). The 115 
mean intensity at starting point was 114.10 ± 10.16; after further 7 days the mean intensity of control 116 
(Ctr) was 134.86 ± 9.25. No significant differences were detected between the control group and the 117 
Hya group (Hya: 152.60 ± 18.70). TNF-α-stimulated samples had a significant decrease of GAGs 118 
regardless of HA presence (TNF: 35.81 ± 9.94, HyaTNF: 82.09 ± 20.51), although HyaTNF showed 119 
less depletion than TNF (P-value = 0.071).  In summary, all these data demonstrated that the model 120 
we used worked properly as a highly useful approach for in vitro cartilage and OA studies. More 121 
importantly, the data showed no inhibiting or activating effect of HA on tissue-engineered normal 122 








Figure 1. Chondrocyte Viability and Cartilage Quality. (A-E) Live-dead staining of micromasses of all 5 
experimental groups. Living cells were stained green using FDA; dead cells were stained red using PI. (F-J) 
Immunohistochemistry demonstrated the presence of cartilage-specific collagen type II (red) as a 
component of the formed matrix. (K-O) Safranin O staining documented the proteoglycan content orange; 
scale bar represents 200 µm 
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2.2. In vitro model verification by cartilage-related markers 145 
In order to gain insight into the gene expression pattern of normal and OA-like micromasses 146 
that have been treated with HA, a microarray analysis with genome-wide Affymetrix GeneChip 147 
porcine arrays was performed. 148 
To verify the suitability of the 3D cartilage micromasses also on the molecular level, the 14-day 149 
micromasses (starting point) were examined for cartilage-related marker genes that were selected 150 
based on the data of our reference model paper (Table 1, d14_ref) [7]. Our expression data showed 151 
the same present-absent pattern in almost all (except for Serpin Family A Member 3, SERPINA3) 152 
selected cartilage markers (Table 1, d14_start point) consisting of collagen type 2, -9 (COL2A1, 153 
-9A1), ECM connectors (hyaluronan and proteoglycan link protein 1; HAPLN1, proline and 154 
arginine-rich end leucine-rich repeat protein; PRELP) and other players of structural integrity of 155 
cartilage (cartilage intermediate layer protein; CILP, cartilage oligomeric matrix protein; COMP), 156 
enzymes (matrix metallopeptidase 3; MMP3, serpin family A member 1; SERPINA1), growth 157 
factors (fibroblast growth factor 2; FGF2, insulin-like growth factor binding protein 3; IGFBP3), 158 
proteoglycans (aggrecan; ACAN, chondroitin sulfate proteoglycan 4; CSPG4), receptors (fibroblast 159 
growth factor receptor 1, -3; FGFR1, -3), and transcription factors (SRY-box 6, -9; SOX6, -9). Further 160 
cultivation up to day 21 (Ctr) did not lead to any changes in this regard (Table 1, d21_Ctr). In favor 161 
of demonstrating OA alterations after TNF-α stimulation, we compared the TNF-α-stimulated 162 
micromasses (TNF) with non-stimulated micromasses (Ctr). Roughly 85% of the 41 selected 163 
cartilage marker genes were significantly up- or downregulated; the fold change (FC) trends are 164 
given in Table 1. These results are in line with our previously published data [7], and with the 165 
Safranin O staining results (Figure 1 K-O). In summary, these extensive similarities and the 166 
cartilage marker gene profiles given in Table 1 proved the reproducibility and suitability of the 167 








Table 1. Overview of gene expression of selected cartilage markers 176 
Figure 2. Histomorphometric analysis of Safranin O stainings of 
all experimental groups considering the proportion and intensity 
of the stained area as the mean intensity normalized to the 
control + standard deviation (n = 3) 
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COL1A2  collagen type I α2 + + + < 
COL2A1 collagen type II α1 + + + << 
COL9A2 collagen type IX α1 + + + << 
ECM 
connectors 
FMOD fibromodulin + + + < 
HAPLN1 hyaluronan and proteoglycan link protein 1 + + + << 
LGALS3 carbohydrate-binding protein 35  + + + > 
PCOLCE2 C-endopeptidase enhancer 2  + + + / 
PRELP prolargin  + + + < 
Enzymes 
MMP3 matrix metallopeptidase 3 + + + >> 
SERPINA1 serpin peptidase inhibitor clade A member 1 + + + << 
SERPINA3 serpin peptidase inhibitor clade A member 3 - + + / 
Growth 
factors 
BMP2 bone morphogenetic protein 2  + + + / 
BMP4 bone morphogenetic protein 4 + + + < 
BMP7 bone morphogenetic protein 7 - - - >> 
FGF18 fibroblast growth factors 18 - - - < 
FGF2 fibroblast growth factors 2  + + + >> 
FGF9 fibroblast growth factors 9 - - - << 
IGF1 insulin-like growth factor 1 + + + < 
IGFBP3 insulin-like growth factor binding protein 3 + + + >> 
TGFB1 transforming growth factor beta 1   + + + < 
TGFB2 transforming growth factor beta 2 + + + > 
TGFB3 transforming growth factor beta 3 + + + < 
THRA thyroid hormone receptor α + + + < 
Proteoglycan 
ACAN aggrecan  + + + << 
BGN biglycan  + + + < 
CSPG4 chondroitin sulfate proteoglycan 4  + + + << 
DCN decorin  + + + < 
HSPG2 heparan sulfate proteoglycan 2  + + + / 
VCAN versican  + + + / 
Receptors 
FGFR1 fibroblast growth factor receptor 1 + + + < 
FGFR2 fibroblast growth factor receptor 2 + + + < 




CHI3L1 chitinase 3-like 1 + + + > 
CILP cartilage intermediate layer protein + + + >> 
COMP cartilage oligomeric protein  + + + << 
ECM1 extracellular matrix protein 1 + + + >> 
FBN1 fibrillin 1  + + + > 
FN1 fibronectin 1  + + + / 
MGP matrix gla protein  + + + < 
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 177 
+ (Bold) = present in all 3 replicates, + = present in some replicates, -  = absent in all replicates, / = no 178 
significant fold change, FC trend = fold change trend from comparison between TNF vs Ctr, < = 179 
downregulation less than 3-fold, << = downregulation more than 3-fold, > = upregulation less than 3-fold, >> = 180 
upregulation more than 3-fold. * = [7] 181 
 182 
2.3. Overview of differentially expressed genes between controls and treated groups 183 
A Venn diagram was drawn to display the overlapping or unique members of the significantly 184 
differentially expressed genes (DEGs) between treated groups and day 21 controls. As shown in 185 
Figure 3, 16 DEGs were upregulated only in the Hya group (Figure 3A) and 6 were downregulated 186 
only in the Hya group (Figure 3B). In HyaTNF, 233 upregulated (Figure 3A) and 241 187 
downregulated DEGs (Figure 3B) did not overlap with the other categories. The intergroup test 188 
detected only 17 upregulated (Figure 3A) and 4 downregulated DEGs (Figure 3B). A comparison 189 
between upregulated DEGs in the HyaTNF and TNF groups revealed 1024 common genes (Figure 190 
3A), and between downregulated differentially expressed genes 1107 common genes. These results 191 
indicated similarities in the gene expression pattern of only HA-treated samples and controls, 192 
whereas TNF-α triggered different gene expression patterns regardless of HA present. 193 
 194 
2.4. Gene expression profiling as response to HA treatment 195 
In order to get a deeper insight into the HA effects, 14-day micromasses that were further 196 
treated for 7 days with HA were compared with non-HA-treated normal and OA-like micromasses. 197 
Hierarchical clustering analysis based on all the probes of day 21 including the HA-treated groups 198 
was performed to explore the variability and similarity of gene expression at day 21 (12 samples), 199 
which therefore showed possible HA effects. Considering the expression pattern of 200 
tissue-engineered cartilage, hierarchical clustering resulted in two main groups, classified as 201 
TNF-α-treated and non-TNF-α-treated (Figure 3C). The clustering showed no distinct clustering for 202 
HA-treated samples, whereas HA-treated (without TNF-α) and normal chondrocytes (Ctr) 203 
clustered together. This similarity indicated that HA did not cause any pronounced alterations in 204 























SOX6 SRY(Sex Determining Region Y)-Box 6  + + + << 
SOX9 SRY(Sex Determining Region Y)-Box 9 + + + / 
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We further analyzed the 47 DEGs detected between Hya and Ctr groups, including 36 276 
upregulated and 11 downregulated genes (Figure 3A, B, and Supplementary Table 1). According to 277 
Figure 3. Figure 3 Gene expression profiling (A) 
Venn diagram of upregulated genes of all 
experimental groups (TNF, Hya, and HyaTNF) 
compared to the control (Ctr).  (B) Venn diagram of 
downregulated genes of all experimental groups 
(TNF, Hya, and HyaTNF) compared to the control 
(Ctr). (C) Hierarchical cluster analysis of all the 
probe sets. Hierarchical cluster analysis 
demonstrated that non-treated (Ctr) and HA-treated 
(Hya) tissue-engineered cartilage formed one cluster 
and TNF-α-treated formed another cluster, showing 
no significant alteration caused by HA. 
79
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the heat map, the HA samples and normal micromasses (Ctr) could be well distinguished using 278 
these screened significantly regulated genes (Figure 3). The most upregulated genes (FC >2.50) are 279 
ankyrin repeat domain 37 (ANKRD37; FC = 3.00), vascular endothelial growth factor A (VEGFA; FC 280 
= 3.00), serpin family E member 1 (SERPINE1; FC = 2.90), solute carrier family 2, member 3 281 
(SLC2A3; FC = 2.80) and the most downregulated genes include MMP3 (FC = -2.00), guanylate 282 
binding protein 1 (GBP1; FC = -1.80), epiphycan (EPYC; FC = -1.70), and angiotensinogen (AGT; FC= 283 
-1.70). 3 genes namely of C-C motif chemokine 2 (CCL2; FC = 2.08), vascular endothelial growth 284 
factor (VEGF; FC = 2.99), and matrix metalloproteinase 3 (MMP3; FC = -1.95) out of these 47 DEGs 285 
are involved in an arthritis pathway showing minor changes in the presence of HA in this context. 286 
To detect the HA effect on OA-like cartilage we performed a comparative microarray analysis, 287 
which identified a total number of 101 genes that were differentially regulated between HyaTNF 288 
and TNF (Table 2). The screened differentially expressed genes were totally enriched in 35 GO 289 
terms, including 5 cellular component (CC) terms, 6 molecular function (MF) terms, and 24 290 
biological process (BP) terms according to the functional annotation. The top 20 terms are shown in 291 
Table 2, which were mainly related to CC terms such as extracellular space and basement 292 
membrane, and genes enriched in these terms included angiopoietin-like 4 (ANGPTL4), apelin 293 
(APLN), C-X-C motif chemokine ligand 3 (CXCL3), IGFBP3, -5, -6, COL4A1, -14A1, extracellular 294 
matrix protein 1 (ECM1), prostaglandin D2 synthase (PTGDS), TIMP metallopeptidase inhibitor 3 295 


































Figure 4. Cluster analysis based on 47 significantly 
differentially expressed genes. Each row depicts a single 
gene; each column a sample. 
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Table 2. The top 20 GO terms sorted according to P value. 333 
 334 






CC GO:0005615 extracellular space 16 3,0E-05 
CXCL3, IGFBP6, LMCD1, PLBD1, 
ECM1, TIMP3, COL14A1, PTGDS, 
SFRP1, HIST2H2BE, GPX3, 
VEGFA, IGFBP3, APLN, 
ANGPTL4, IGFBP5 
MF GO:0001968 fibronectin binding 3 2,3E-04 VEGFA, IGFBP3, IGFBP5 
MF GO:0031994 
insulin-like growth factor I 
binding 
3 3,4E-04 IGFBP6, IGFBP3, IGFBP5 
MF GO:0031995 
insulin-like growth factor 
II binding 
3 3,4E-04 IGFBP6, IGFBP3, IGFBP5 
BP GO:0043567 
regulation of insulin-like 
growth factor receptor 
signaling pathway 
3 6,9E-04 IGFBP6, IGFBP3, IGFBP5 
CC GO:0005604 basement membrane 4 1,8E-03 P3H2, COL4A1, ITGA6, TIMP3 
BP GO:0071456 
cellular response to 
hypoxia 
4 2,1E-03 PTGS2, SFRP1, VEGFA, ANGPTL4 
BP GO:0045663 
positive regulation of 
myoblast differentiation 
3 3,7E-03 CDON, BOC, IGFBP3 
BP GO:0045892 




CRY2, SFRP1, BEND5, CCDC85B, 
BASP1, HMGA1 
CC GO:0005576 extracellular region 8 9,7E-03 
FGF7, PTGDS, PAPPA, AGT, NMB, 
FGF13, CFD, GHR 
BP GO:0001558 regulation of cell growth 3 1,4E-02 IGFBP6, IGFBP3, IGFBP5 
BP GO:0017148 
negative regulation of 
translation 
3 1,7E-02 BTG2, ENC1, IGFBP5 
CC GO:0042567 
insulin-like growth factor 
ternary complex 
2 1,9E-02 IGFBP3, IGFBP5 
CC GO:0070062 extracellular exosome 18 2,2E-02 
SCPEP1, IGFBP6, NPR3, ECM1, 
TIMP3, ARG1, COL14A1, BTG2, 
SFRP1, PTGDS, RAB19, 
HIST2H2BE, AGT, PCBP2, BLVRB, 
GPX3, IGFBP3, MEST 
BP GO:0044342 
type B pancreatic cell 
proliferation 
2 3,5E-02 IGFBP3, IGFBP5 
BP GO:0014912 negative regulation of 2 3,5E-02 IGFBP3, IGFBP5 
81
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smooth muscle cell 
migration 
BP GO:0006979 response to oxidative stress 3 3,8E-02 PTGS2, GPX3, SRXN1 
BP GO:0043568 
positive regulation of 
insulin-like growth factor 
receptor signaling pathway 
2 4,0E-02 IGFBP3, IGFBP5 
BP GO:0045893 




FGF7, SFRP1, AGT, SERTAD3, 
HMGA1 
 335 
3. Discussion 336 
The present conflicting data regarding the controversial properties of HA, gold standard 337 
viscosupplement for OA [8], encouraged us to investigate more thoroughly its physiologic effect on 338 
cellular and molecular level. Although exogenous HA application has been studied before during in 339 
vitro cartilage formation [9] this study has been the first, to perform a global gene expression 340 
analysis on HA-treated normal and OA-like tissue-engineered cartilage. Our findings showed no 341 
inhibiting or activating effect of HA on tissue-engineered normal or OA-like cartilage on the 342 
cellular level. On the molecular lever, we could observe minor changes in arthritis context but no 343 
pronounced alterations were caused by HA. We could also confirm that the OA model we used was 344 
a highly useful approach for in vitro cartilage and OA studies. 345 
Live-dead staining of 14-day micromasses, which were further treated for 7 days with 0.3 346 
wt.%. HA in normal and OA-like conditions (where TNF-α was added to simulate important 347 
aspects of OA), revealed a majority of viable cells embedded in ECM. A normal morphology and 348 
even distribution of cells through the matrix was observed in all experimental groups. This meant 349 
HA did not cause any cell death stimulation under normal and OA-like conditions compared to 350 
control group and starting point. We used 0.3 wt.% concentration of HA to mimic the in vivo 351 
situation, because in healthy human synovial fluid, a broad range of HA concentrations was 352 
measured ranging between 0.05 and 0.4 wt.%, with 0.3 wt.% being typical [10]. Collagen type II 353 
immunostaining did not reveal any specific differences between experimental groups, which is in 354 
line with the previous published data [7]. It has been shown that the total collagen loss was not 355 
pronounced in this model and HA did not seem to change this pattern either. Smyth et al. have 356 
recently shown in a rabbit model that addition of HA caused no noticeable difference in the type-II 357 
collagen immunoreaction between the HA-treated grafts and the controls [11]. Proteoglycan 358 
depletion plays a main role in the histopathological assessment of OA grade [12] and is a detectable 359 
feature in this model. Addition of TNF-α, a well-known mediator of acute inflammation in cartilage 360 
pathology, triggered a clear depletion of GAG in HA-treated as well as non-treated micromasses. 361 
However, there was less decrease of GAG observed in HyaTNF. This can be explained by the study 362 
of Greenberg et al. who concluded from their cartilage synovium co-culture model that HA inhibits 363 
the MMP- and IL-1-mediated decrease in glycosaminoglycan production by cartilage explants [13] 364 
and this chondroprotective effect was further confirmed by Elmorsy et al. in vivo [4]. These 365 
observations in connection with gene expression alterations caused by addition of TNF-α (Table 1) 366 
showed the feasibility of the porcine micromass model to assess HA influence on normal and OA 367 
cartilage. 368 
Comparative genome-wide expression analysis of porcine micromasses treated with HA and 369 
the non-treated micromasses revealed a total of 47 dysregulated genes (Figure 3) including 370 
up-regulation of ANKRD37, VEGFA, SERPINE1, SLC2A3 as well as gene coding for chemokine 371 
CCL2 and downregulation of MMP3, GBP1, EPYC, and AGT. ANKRD37 is associated with hypoxia 372 
and cell respond to hypoxic environment is upregulation of ANKRD37 RNA. Here the HA 373 
provoked the same response. It has been shown that this could lead to increased cartilage-specific 374 
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gene expression, e.g., aggrecan and Sox9 [14]. This could be the reason why we observed a 375 
insignificant increase in GAG content of HyaTNF. VEGFA has a role in cartilage maturation and is 376 
critical for chondrocyte survival [15] .Its upregulation in this study together with ANKRD37 377 
upregulation confirms the existing findings that HA can act chondroprotectively [16]. SERPINE1 378 
has a function in complement cascade and its upregulation has been reported in OA-affected 379 
cartilage [17]. SLC2A3 encodes GLUT3, a glucose transporter, and plays an essential role in 380 
chondrocyte metabolism and physiology and can also be upregulated as a result of hypoxia. This 381 
hypoxia-like influence of HA can be explained due to its high viscosity that restrains the diffusion 382 
of oxygen. Interestingly, MMP3 which is considered to be the crucial enzyme in matrix turnover 383 
(ECM degradation) and has elevated levels in OA [18, 19] has a 2-fold downregulation in 384 
HA-treated group, which is in line with previous studies that claimed HA has the potential to 385 
inhibit the activity of matrix metalloproteinases and catabolic cytokines [20]. GBP1 is an 386 
enzyme-binding protein, which showed an increase under rheumatoid arthritic conditions [21] and 387 
HA-treated micromasses showed the reverse trend. We have also observed the downregulation of 388 
EPYC, which is a marker enriched in growth plate cartilage and is used to identify hyaline cartilage 389 
subtype [22].  390 
We have further compared gene expression of HyaTNF group to TNF in order to study the 391 
genes that are dysregulated by HA treatment under OA conditions. We found an increased level of 392 
IGF-binding proteins (IGFBP) in HyaTNF. Insulin-like growth factor-1 (IGF-1) is the most likely 393 
candidate to affect the anabolism (synthesis of both collagen type II and proteoglycan core protein) 394 
of cartilage matrix molecules and IGFBPs have a high affinity for IGF-1 [23]. From our data (Table 395 
2) we can conclude that HA can possibly influence the cartilage anabolism via binding to IGFs and 396 
stabilize the chondrocyte phenotype in pathological conditions. CXCL3 chemokine has been 397 
reported to have an increased expression in OA cartilage [24]. HA seems to hamper this event by 398 
FC = -2. GPX3 is involved in oxidative damage defense and is downregulated in OA cartilage [25]. 399 
In our study HA appears to amplify this trend (FC = -2.6) in OA-like cartilage but not in healthy 400 
micromasses, which shows that the effect is caused by TNF-α addition and not HA.  401 
HA with different molecular weight and consistencies are known to have different clinical 402 
outcomes. In our study, we used one type of HA, namely; OSTENIL®. Therefore further 403 
investigation of more HAs with different molecular weights and concentrations is necessary. 404 
Based on our previous study, a sulfated polyether hydrogel with anti-inflammatory properties 405 
has viscoelastic properties that are comparable to HA for intra-articular injection, where for medical 406 
applications the above-mentioned hydrogel has the advantage of being much less easily displaced 407 
from its injection place than HA [26]. Comparing HA with such alternative candidates that have 408 
disease-modifying properties is required for the development of better therapeutics.  409 
 410 
4. Materials and Methods  411 
 412 
4.1. Chondrocyte isolation 413 
Chondrocytes were isolated from the medial and lateral femoral condyle of domestic pigs (9 414 
donors). In each case, cells from 3 donors were pooled together (n = 3 pools). No animal approval 415 
was needed because the samples were obtained from a local slaughterhouse. Chondrocytes were 416 
isolated according to a previously published protocol [27]. Briefly, cartilage pieces were incubated 417 
for 19 h in spinner flasks containing RPMI medium, supplemented with 10% fetal bovine serum 418 
(FBS, Thermo Fisher Scientific, Dreieich, Germany), 100 U/ml penicillin (Pen) and 100 µg/ml 419 
streptomycin (Strep), 333.3 U/ml collagenase II (all Merck, Darmstadt, Germany), 1 U/ml 420 
collagenase P (Roche Diagnostics, Mannheim, Germany), and 33.3 U/ml hyaluronidase 421 
(Sigma-Aldrich, Steinheim, Germany). Afterwards, cell suspensions were filtered through a 100 µm 422 
nylon mesh (Becton Dickinson, Heidelberg, Germany), washed in Hanks solution (Merck), and 423 
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resuspended in culture medium consisting of RPMI, 10% FBS, 100 U/ml Pen, 100 µg/ml Strep and 424 
170 µM L-ascorbic acid (Sigma-Aldrich). 425 
 426 
4.2. Preparation of 3D-chondrocyte micromass cultures 427 
A volume of 200 µl containing 6*105 freshly isolated chondrocytes (pooled from 3 donors) in 428 
culture medium was transferred to each well of 96-well flat bottom plates (Becton Dickinson) to 429 
generate a high-density micromass culture (tissue-engineered cartilage) [7]. Subsequently, the 430 
culture plates were incubated for 24 h (37 °C, 5% CO2) to ensure cell sedimentation. The medium 431 
was changed daily. Micromasses were allowed to form ECM for 14 days and then were treated for 432 
further 7 days with HA alone (MW=1.2 KDa; OSTENIL®, TRB Chemedica, Germany), TNF-α alone 433 
(R&D Systems, Wiesbaden, Germany) to induce OA-like changes, or in combination thereof. This 434 
resulted in 5 experimental groups: (1) micromasses cultured for 14 days (start point) and (2) further 435 
cultured for 7 days without treatment (control; Ctr) or treatment (3) with 0.3 wt.% HA diluted in 436 
culture medium (Hya), (4) 0.6 nmol/l TNF-α diluted in culture medium, or (5) a combination of (3) 437 
and (4) (HyaTNF).  438 
 439 
4.3. Live/dead assay 440 
To demonstrate the cell viability of the micromasses, propidium iodide/fluorescein diacetate 441 
(PI/FDA) staining (Sigma-Aldrich) was performed. The micromasses were washed with PBS and 442 
stained with FDA under darkness. To prepare the FDA staining solution 1 mg/ml FDA were 443 
dissolved in acetone and further diluted to a concentration of 3 µg/ml in PBS. Then, the samples 444 
were rinsed with PBS before being counterstained with PI. To prepare the PI staining, 1 mg/ml PI 445 
were dissolved in distilled water and further diluted to a concentration of 0.1 mg/ml in PBS. After 446 
an additional washing step, the micromasses were analyzed under a fluorescent microscope 447 
(Olympus AX70, Hamburg, Germany). 448 
 449 
4.4. Histological and immunohistochemical staining 450 
To document ECM formation or loss, micromasses that were embedded in an optimal cutting 451 
temperature compound (Sakura Finetek, Staufen im Breisgau, Germany) were cryosectioned at 8 452 
µm and mounted on glass slides. Sulfated cartilage glycosaminoglycans (GAGs) were stained with 453 
0.7% Safranin O in 67% ethanolic solution, and cell nuclei were counterstained with 0.2% Fast 454 
Green in 0.3% acetic acid. Stainings were photodocumented using a light microscope (AX 10, Zeiss, 455 
Jena, Germany).  456 
The intensity of the Safranin O staining is directly proportional to the GAG amount of the 457 
tissue and can therefore be called a semi-quantitative histochemical method [28]. Therefore a 458 
histomorphometric analysis was performed as previously described [7]. Briefly, pictures were taken 459 
and all pixels in the areas of interest were valued in the RGB color mode with a tool based on Xcode 460 
(Apple, Sunnyvale, CA, USA). When the red value (R) multiplied by 2 was higher than the sum of 461 
the green (G) and blue (B) values, the pixel was counted as red. The intensity of each red pixel was 462 
calculated with this formula: intensity = 2 x R-value - G-value - B-value. Values of the intensity 463 
ranged between 1 and 510. The mean intensity (sum of intensities/area of interest) was calculated 464 
from each image. 465 
Collagen type II expression was analyzed by immunohistochemistry with polyclonal mouse 466 
anti-porcine type II collagen antibodies (Calbiochem CP18, Merck). Mouse IgG (DAKO, Hamburg, 467 
Germany) served as a control. EnVision detection antibody was used to visualize collagen type II 468 
antibodies and nuclei were counterstained with hematoxylin (DAKO). 469 
 470 
4.5. RNA Isolation  471 
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Total RNA was isolated from micromasses that were cultured over 21 days. For each 472 
individual replicate (n = 3) of each experimental group, 5 micromasses were snap-frozen in liquid 473 
nitrogen, and stored at -80°C until further use. The frozen samples were transferred to 1 ml 474 
TriReagent (Sigma-Aldrich) and mechanically homogenized. Subsequently, 133µl 475 
1-bromo-3-chloro-propane (Sigma-Aldrich) was admixed followed by centrifugation for 45 minutes 476 
at 13,000 g. The aqueous phase was collected and supplemented with same volume of 70% ethanol. 477 
Further purification was performed according to protocol for animal tissues of  the RNeasy Mini 478 
Kit (Qiagen, Hilden, Germany). The RNA concentration was determined by the Nanodrop 1000 479 
spectrophotometer (Thermo Fisher Scientific). The integrity of the RNA was determined by the 480 
Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The RNA samples used in 481 
this study had an integrity number above 8.9.  482 
 483 
4.6. Microarray analysis 484 
Altogether, data from 15 microarray experiments (5 groups in triplicates) are included in this 485 
study, from which selected data of 6 microarrays (triplicates of Ctr and TNF groups) have already 486 
been submitted[29] to ''Journal of Biomedical Materials Research Part B: Applied Biomaterials'' a 487 
study with the totally different focus on sulfated polyethyleneglycol hydrogels as a possible HA 488 
alternative.  489 
A total of 23,937 probe sets representing 20,201 porcine genes were covered in the Affymetrix 490 
GeneChip porcine array (Affymetrix, Freiburg, Germany). RNA processing and hybridization were 491 
performed according to the manufacturer’s protocol. The GeneChips were scanned with the 492 
Affymetrix GeneChip scanner 3000. Raw gene expression data were normalized and analyzed with 493 
GeneChip operating software 1.4 (GCOS, Affymetrix). Comparisons between triplicates of the 494 
starting point group and the Ctr group were performed on the basis of a cartilage-marker list 495 
associated with our in vitro OA model [7]. Other paired group comparisons were performed 496 
between replicates of each group (9 comparisons). Genes were selected for further analysis that 497 
showed (1) a significant signal change, which was detected by GCOS for at least 7 out of 9 498 
comparisons, (2) a 1.5 mean-fold change, and (3) a p-value < 0.05 applying t-test. To group genes 499 
with coherent expression profiles into modules, we used complete linkage hierarchical clustering 500 
(HCL) with normalized log 2-transformed signals. A Pearson correlation was done to determine the 501 
distance measure and complete linkage clustering by agglomeration rule, using Genesis 1.7.6 502 
software [30]. Gene ontology (GO) terms analysis, biological process (BP) function enrichment 503 
analysis, and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis of 504 
differentially expressed genes was performed using the database for annotation, visualization, and 505 
integrated discovery (DAVID) [31]. In order to find the names for unnamed porcine probe set IDs, 506 
we used cross-species relationships between porcine and human probe set IDs 507 
(U133PlusVsPorcine_Complex sheet) in combination with human NetAffx annotation file 508 
(HG_U133_Plus_2 Array, Affymetrix).  509 
 510 
4.7. Statistical Analysis.  511 
The intensity of the Safranin O stained areas are shown as the mean intensity normalized to the 512 
control and standard deviation. A P value lower than 0.05 was accepted as statistically significant. 513 
The significance level of log 2-tranformed microarray data was determined with the independent 514 
two sample t-test statistics of the Excel 2011 software package (Microsoft, Redmond). The normality 515 
of distribution was investigated applying the Anderson-Darling test [32], and the equal variance of 516 
the compared sample groups was tested applying the f test [33, 34]. The data showed normal 517 
distribution with equal variance, therefore t-test was applied. Differences were considered 518 
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The raw data is available for presentation to the referees and the editors of the journal, if 522 
requested. The microarray data will be deposited in the GEO database. 523 
5. Conclusions 524 
In conclusion, the present study can further confirm that HA does not have a great 525 
physiological impact on normal and OA-like tissue-engineered cartilage.  Nevertheless it can 526 
possibly influence the cartilage anabolism via stabilizing the chondrocyte phenotype in pathological 527 
conditions. Moreover, the upregulation of VEGFA and ANKRD37 genes confirms the 528 
chondroprotective potential of HA and slow down degradation. Understanding these HA-related 529 
modifications may serve as a guide toward imminent therapies. In addition to providing 530 
mechanistic evidence, the results in this study further validate the feasibility of in vitro OA model 531 
for the investigation of HA. 532 
 533 
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ANGPTL4 included angiopoietin-like 4 
ANKRD37 ankyrin repeat domain 37 
APLN apelin 
BP biological process 
CC cellular component 
CCL2 C-C motif chemokine 2 
CD44 cluster of differentiation 44 
CILP cartilage intermediate layer protein 
COL2A1 collagen type 2 alpha 1 chain 
COL9A1  collagen type IX alpha 1 chain 
COMP cartilage oligomeric compound 
CSPG4 chondroitin sulfate proteoglycan 4 
CXCL3 C-X-C motif chemokine ligand 3 
DAVID database for annotation, visualization, and integrated discovery 
ECM extra cellular matrix 
EPYC epiphycan 
FBS fetal bovine serum 
FC fold change 
FGF fibroblast growth factor 
FGFR fibroblast growth factor receptor  
GAG glycosaminoglycan 
GBP1 guanylate binding protein 1 
GCOS GeneChip operating software 
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GO gene ontology 
HA hyaluronic acid 
HAPLN1 hyaluronan and proteoglycan link protein 1 
HCL hierarchical clustering 
IGFBP insulin-like growth factor binding protein  
IL interleukin 
KEGG Kyoto encyclopedia of genes and genomes 
MF molecular function 
MMP matrix metalloproteinase 
OA osteoarthritis 
Pen penicillin 
PI/FDA propidium iodide/fluorescein diacetate 
PRELP proline and arginine-rich end leucine-rich repeat protein 
PTGDS prostaglandin D2 synthase 
SERPINA serpin family A member  
SFRP1 secreted frizzled related protein 1 
SLC2A3 solute carrier family 2 member 3 
SOX SRY-Box 
Strep streptomycin 
TIMP3 TIMP metallopeptidase inhibitor 3 
TNF-α tumor-necrosis factor-alpha 
VEGFA vascular endothelial growth factor A 
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4 Summary and Outlook 
 
The aim of this thesis was to investigate the potential of a fully synthetic, slowly degradable, 
heparin sulfate mimetic hydrogel as an alternative viscosupplement for OA management and 
thereby compare it to the current standard viscosupplement HA. 
 A previous study revealed a short half-life of HA, ranging from half a day up to 9 days 
in vivo.[65] To avoid several injections, which may incur higher costs and infection risks, a 
fully synthetic dendritic polyglycerol sulfate (dPGS) hydrogel was evaluated for its 
bioorthogonality. The rheological properties of this slow-degradable hydrogel were then 
investigated to determine a suitable concentration for intra-articular injections that mimicked 
HA in terms of its viscoelastic and mechanical properties. Therefore, different concentrations 
of dPGS ranging from 3.6 to 4.8 wt% were investigated by means of oscillating and flow 
rheology, thereby yielding storage (G') and loss modulus (G''), as well as yield stress and 
shear viscosity. Additionally, blends of commercially available HAs, which varied in respect 
to their molecular weight, were used as references. As a result, a pronounced coupling of the 
molecular weight and the rheological properties for the HAs was observed. The zero shear 
viscosity of the studied HAs ranged between 5 and 1600 Pa⋅s, depending strongly on the 
molecular weight. Besides, all four HA samples exhibited pronounced shear thinning 
behavior. Furthermore, the dPGS hydrogel formed more compact networks with increasing 
concentrations. From a broader comparison, the current findings suggest that an overall 
polymer concentration of 4.0 wt% dPGS has viscoelastic properties that are comparable to 
HA in the medically relevant frequency range.  
 The third part of the thesis was focused on the evaluation of dPGS effects on normal 
and OA-like tissue-engineered cartilage. To overcome the low availability of human primary 
tissue and high costs of animal models an established in vitro OA model has been used. It is 
based on porcine cartilage sources and offers a high-throughput analysis of potential active 
substances in a reproducible and very well characterized approach under standardized 
conditions.[140, 144] In this model, micromass cultures were treated with 2.5 wt% dPGS 
hydrogel for 7 days under normal and OA conditions (treated with TNF-α). Live/dead 
staining of micromasses revealed a majority of viable cells embedded in ECM after 7 days of 
treatment with the hydrogel in normal and OA conditions. This confirmed previous findings 
and suggested that dPGS was not harmful for different cell types and even in vivo.[145] 
Safranin-O staining demonstrated a typical depletion of GAGs in OA-like micromasses but 
not in the presence of the dPGS hydrogel. There was no distinct difference in immunolabeling 
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for type II collagen. The microarray data showed that rheumatoid arthritis and TNF signaling 
pathways were downregulated in hydrogel-treated OA-like micromasses in comparison to 
non-treated OA-like micromasses. Furthermore, the dPGS hydrogel alone did not affect genes 
related to OA such as ANPEP, COMP, CXCL12, COX2, and TNFSF10, but it could prevent 
their regulation caused by TNF-α. These findings proved the potential of this hydrogel to 
prevent the development of TNF-α-induced OA with regard to PG loss and TNF-α-induced 
expression pattern without additional signs of differentiation and inflammation. 
 In the fourth part of this work, the HA-related modifications were investigated on 
cellular and molecular level in the same in vitro system to serve as a control for comparisons 
with the dPGS hydrogel. The data showed no inhibiting or activating effect of HA on normal 
or OA-like tissue-engineered cartilage on cellular level. Microarray data demonstrated a 
minor impact of HA on gene expression level. The upregulation of VEGFA and ANKRD37 
genes confirmed the chondroprotective potential of HA. It could regulate the cartilage 
anabolism by stabilizing the chondrocyte phenotype in pathological conditions.  
 In conclusion, the evaluation of the dPGS hydrogel showed that it is a potential 
alternative for HA as an intra-articular injectable lubricant for osteoarthritis. Moreover, in 
contrast to HA, dPGS can prevent the development of TNF-α-induced OA with regard to 
proteoglycan loss and TNF-α-induced expression pattern.  
 Although interactions of dPGS-hydrogels with biological systems have been elucidated 
to a certain extent, still a lot of open questions remain, especially concerning the in vivo effect 
on synovial joints. To follow up these promising results, further investigation needs to be 
performed in animal models. In particular, the localization of this hydrogel in the synovial 
joint should be further investigated by fluorescent dye conjugation and its anti-inflammatory 
properties by measuring the related cytokine ratios in the synovial fluid. Since it is known that 
hydrogels can be used as a delivery system, this hydrogel can also be further optimized with 
biologics to trigger in situ regeneration. 
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5 Kurzzusammenfassung  
 
Das Ziel dieser Arbeit war es, das Potenzial eines vollsynthetischen, langsam abbaubaren, 
dPGS-basierten Hydrogels als alternatives Viskosupplement für die Arthrose (OA) zu 
untersuchen und es mit Hyaluronsäure (HA), der aktuellen Standardtherapie zu vergleichen. 
 HA hat eine kurze Halbwertszeit von einem halben bis zu neun Tagen in vivo.[65] Um 
mehrfache Injektionen und die damit möglichen höheren Kosten und Infektionsrisiken zu 
vermeiden, wurde ein synthetisches dendritisches Polyglycerolsulfat (dPGS) Hydrogel auf 
seine Bioorthogonalität hin untersucht. Anschließend wurden die rheologischen 
Eigenschaften eines langsam abbaubaren dPGS-Hydrogels untersucht. Dabei sollte eine 
Gesamtpolymerkonzentration identifiziert werden, welche die viskoelastischen und 
mechanischen Eigenschaften von HA nachahmt. Die Konzentration wurde im Bereich von 3,6 
bis 4,8 Gew.-% dPGS variiert und mittels Oszillations- und Fließrheologie zur Messung des 
Speicher- (G') und Verlustmoduls (G'') sowie der Fließspannung und Scherviskosität 
untersucht. Als Referenz wurden HAs verschiedener Hersteller verwendet, die sich 
hinsichtlich ihres Molekulargewichts unterscheiden. Als Ergebnis wurde eine ausgeprägte 
Korrelation des Molekulargewichts mit den rheologischen Eigenschaften der HA-Proben 
beobachtet. Die Nullscherviskosität der untersuchten HA-Proben lag zwischen 5 und 1600 
Pa⋅s, Weiterhin wiesen alle vier HA-Proben ein ausgeprägtes Scherverdünnungsverhalten auf. 
Darüber hinaus bildete das dPGS-Hydrogel mit zunehmender Konzentration kompaktere 
Netzwerke aus. Nach Berücksichtigung der unterschiedlichen Viskosität von HA und dPGS-
Hydrogelen konnten bei einer Gesamtpolymerkonzentration von 4,0 Gew.-% dPGS 
viskoelastische Eigenschaften nachgewiesen werden, die mit HA im medizinisch relevanten 
Frequenzbereich vergleichbar sind.  
 Der dritte Teil der Arbeit konzentrierte sich auf die Evaluierung von dPGS-Effekten 
anhand eines etablierten in vitro OA-Modells. Dieses basiert auf Schweineknorpelzellen und 
ermöglicht aufgrund der leichten Verfügbarkeit und geringen Kosten eine 
Hochdurchsatzanalyse in einem reproduzierbaren und sehr gut charakterisierten Ansatz unter 
standardisierten Bedingungen.[140, 144] In diesem Modell wurden Mikromassenkulturen 7 Tage 
mit 2,5 Gew.-% dPGS-Hydrogel unter Normal- und OA-Bedingungen (induziert duch TNF-
α) behandelt. Lebend/Tot Färbungen zeigten eine hohe Vitalität der Zellen nach 7 Tagen der 
Behandlung mit Hydrogel unter normalen und OA-Bedingungen. In Übereinstimmung mit 
früheren Ergebnissen legt dies nahe, dass dPGS für verschiedene Zelltypen und sogar in vivo 
sehr gut verträglich ist.[145] Die Safranin-O-Färbung zeigte eine typische Abnahme der GAGs 
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unter OA-ähnlichen Bedingungen, jedoch nicht in Gegenwart des Hydrogels. Ein Unterschied 
in der Immunmarkierung für Typ-II-Kollagen konnte nicht festgestellt werden. Die 
genomweite Genexpressionsuntersuchung mittels Mikroarray zeigte, dass rheumatoide 
Arthritis und TNF-Signalwege in hydrogelbehandelten OA-ähnlichen Mikromassenkulturen 
im Vergleich zu unbehandelten herunterreguliert wurden. Außerdem hatte das Hydrogel allein 
keinen Einfluss auf Gene, die mit OA in Verbindung stehen, wie ANPEP, COMP, CXCL12, 
COX2 und TNFSF10. Es konnte aber ihre TNF-α induzierte Regulation verhindern. Die 
Ergebnisse zeigen die Biokompatibilität und das Potenzial dieses Hydrogels, die Entwicklung 
TNF-α-induzierter OA im Hinblick auf Proteoglykanverlust und TNF-α-induzierte 
Expressionsmuster ohne zusätzliche Differenzierungs- und Entzündungszeichen zu 
verhindern. 
 Im vierten Teil dieser Arbeit wurden die HA-bezogenen Modifikationen auf zellulärer 
und molekularer Ebene im gleichen in vitro System untersucht, um als Kontrolle für den 
Vergleich mit dem dPGS-Hydrogel zu dienen. Die Daten zeigten auf zellulärer Ebene keine 
inhibierende oder aktivierende Wirkung von HA auf normalen oder OA-ähnlichen, in vitro 
generiertem Knorpel. Mikroarray-Daten zeigten einen geringen Einfluss von HA auf die 
Genexpression. Die Hochregulation der Gene VEGFA und ANKRD37 bestätigt das 
chondroprotektive Potenzial von HA. Es stimuliert geringfügig den Knorpelanabolismus, 
indem es den Chondrozytenphänotyp unter pathologischen Bedingungen stabilisiert.  
 Zusammenfassend zeigte die Evaluierung vom dPGS-Hydrogel, dass es eine potentielle 
Alternative für HA als intraartikuläres injizierbares Schmiermittel für OA ist. Darüber hinaus 
kann dPGS im Gegensatz zu HA die Entwicklung von TNF-α-induzierter OA im Hinblick auf 
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